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Scope of this thesis 
In the past years several new therapeutic interventions in breast cancer were 
investigated and some were consecutively implemented in daily practice.  
The introduction of systemic chemotherapy resulted in a modest improvement in the 
outcome of patients with disseminated breast cancer. Although the majority of 
patients with metastatic breast cancer will experience an initial response or 
stabilization of the disease on various combination chemotherapy regimens, relapses 
mostly occur within one year and the median overall survival after start of treatment 
is limited to on average two to three years. Attempts to improve these results by 
increasing the dose of chemotherapy has met only limited success, mainly due to 
profound myelosuppression. Hematopoietic growth factors, and particularly 
Granulocyte Colony Stimulating Factor (G-CSF), offer an opportunity to overcome this 
problem, but whether this will lead to better results remains to be determined. The 
aim of dose intensification is to increase the dose of treatment to the limit of normal 
tissue tolerance for the drugs used, with the intention of maximizing antitumor 
efficacy. Dose intensity, dose size and cumulative dose may each have important but 
different effects on outcome. According to the analysis of Goldie and Coldman the 
major effect of increased dose intensity is a more rapid and effective eradication of 
sensitive tumor cells, and with the dose size being the most important factor in 
reducing the chance of developing resistant cells.   
Norton showed that a Gompertzian growth model precisely fitted in the growth 
curves of breast cancer. In this model, when a patient with advanced breast cancer is 
treated and the tumor mass is large, its growth fraction is low and the fraction of cells 
killed is low. Shortening of intervals ("dose-dense chemotherapy") may be important 
to overcome this cytokinetic resistance of tumors, by killing chemosensitive cells and 
recruiting regrowth of dormant cells, which will be killed by the subsequent cycle.  
G-CSF can be used to obtain increased chemotherapy dose-intensity by allowing a 
higher dose of chemotherapy per course (dose-escalation) or by allowing a shortening 
of interval between courses (dose-dense). Both approaches may lead to a higher 
dose-intensity, but their biological effect and thereby clinical relevance may be quite 
different as has been pointed out by Henderson in his review on the dose-intensity 
phenomenon in breast cancer. The relative merits of these two approaches have not 
been studied systematically. 
 
Chapter 2: “Comparative study of dose escalation versus interval reduction to obtain 
dose intensification of epirubicin and cyclophosphamide with Granulocyte-Colony 
Stimulating Factor (G-CSF) in advanced breast cancer” describes a randomized study 
with the aim to compare the maximal dose intensity of epirubicin and 
cyclophosphamide with the support of  G-CSF, if given with fixed doses and decreasing 
intervals or with increasing doses and fixed intervals. The second aim was to assess 
the safety profiles of these intensified schedules. 
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Anthracyclines and taxanes belong to the most active single agents in advanced breast 
cancer. Paclitaxel is highly active and lacks cross-resistance with other drugs 
commonly used in breast cancer treatment.  
 
Chapter 3, “Dose dense epirubicin and paclitaxel with G-CSF: a study of decreasing 
intervals in metastatic breast cancer”, describes a study with the aim of increasing 
the dose-intensity of the epirubicin and paclitaxel combination by shortening of the 
cycle time. The objective was to define the shortest feasible chemotherapy interval 
and to assess the safety profile of this approach. 
 
Chapter 4, “Epirubicin and paclitaxel with G-CSF support in first line metastatic 
breast cancer: A randomized phase II study of dose-dense and dose-escalated 
chemotherapy”, evaluates the efficacy and tolerability of two different dose-
intensified chemotherapy regimens of epirubicin and paclitaxel, supported with 
G-CSF.  
 
Adjuvant chemotherapy has demonstrated a modest, but consistent improvement in 
long term disease-free and overall survival in primary breast cancer patients. The 
prognosis of patients with early breast cancer is inversely related to the number of 
involved axillary lymph nodes at surgery. Analysis of treatment outcomes in patients 
with 4-9 positive lymph nodes indicates that 60-70% will relapse by 10 years and for 
patients with 10 or more positive lymph nodes this is even worse, at 10 years 70-90% 
will have relapsed if no additional systemic treatment is provided. Attempts to further 
improve these results by increasing the dose of chemotherapy have met only limited 
success, mainly due to profound myelosuppression. Autologous stem cell 
transplantation offers an opportunity to overcome this problem, but whether this will 
lead to better results remains to be determined.  
 
In Chapter 5, “High-dose chemotherapy with autologous bone marrow support as 
consolidation after standard-dose adjuvant therapy in primary breast cancer 
patients with 7 or more involved axillary lymph nodes”, the question is being 
addressed whether adjuvant chemotherapy followed by high dose consolidation with 
busulfan and cyclophosphamide supported by autologous stem cell transplantation 
may improve the prognosis of patients with early breast cancer and 7 or more positive 
axillary lymph nodes.  
 
In an addendum, the long-term follow-up data of the study of high-dose 
chemotherapy with autologous stem cell transplantation in high risk early breast 
cancer is given, with an overview of the literature on the role of high dose 
chemotherapy with autologous stem cell transplantation in the treatment of breast 
cancer.  
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Chapter 6: “HLA-matched allogeneic stem cell transplantation after reduced 
intensity (RIST) conditioning with Fludarabine/CTX in patients with metastatic 
breast cancer”, describes the largest single centre experience with RIST allogeneic 
stem cell transplantation in metastatic breast cancer. Purpose of this single centre 
study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. 
Allogeneic transplantation of hematopoietic stem cells from an HLA-compatible donor 
has become the standard of care for several hematologic malignancies. Allogeneic 
transplantation not only replaces the marrow affected by the disease, but also exerts 
an immune graft-versus-tumor effect mediated by donor lymphocytes. The 
development of reduced intensity or non-myeloablative conditioning regimens for 
allogeneic transplantation has allowed this therapy to be used in elderly and disabled 
patients. An allogeneic graft-versus-tumor effect is observed in a proportion of 
patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with 
allogeneic transplantation. 
 
Finally, Chapter 7 provides a summary and future perspectives. 
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Summary 
Aims 
A potential application of hematopoietic growth factors is to obtain an increased dose intensity. This can 
be achieved by either higher doses of chemotherapy with standard intervals, or by standard doses with 
shorter intervals. The potential of these approaches has not been investigated systematically. 
 
Patients and methods 
In a randomized, multicenter study, forty nine advanced breast cancer patients were treated with G-CSF 
and either increasing doses of epirubicin and cyclophosphamide with fixed intervals (arm 1) or 
progressively shorter intervals with fixed doses of epirubicin and cyclophosphamide (arm 2). A cohort of at 
least six patients was studied at each interval/dose. A more intensified interval/dose was given if less than 
50% of patients encountered a dose intensity limiting criterium in the first three courses. 
 
Results 
In arm 1, epirubicin/cyclophosphamide 140/800 mg/m2 q 21 days was too toxic. Subsequently 
epirubicin/cyclophosphamide 120/700 mg/m2 was tested with two out of ten patients encountering a dose 
intensity limiting criterium. All initial dose intensity limiting criteria consisted of febrile neutropenia. In 
arm 2, epirubicin/cyclophosphamide 75/500 mg/m2 could be administered safely with fourteen and twelve 
days intervals. In the ten days interval eight out of twelve patients completed the first three cycles without 
a dose intensity limiting criterium. In the eight days interval seven out of eight patients encountered a dose 
intensity limiting criterium. Incomplete neutrophil recovery, and to a lesser extent stomatitis, were dose 
limiting.  
 
Conclusions 
In combination with G-CSF, epirubicin/cyclophosphamide 120/700 mg/m2 q 21 days was feasible with a 
projected dose intensity of 40 mg/m2/week and 233mg/m2/week, respectively.  
Epirubicin/cyclophosphamide 75/500 mg/m2 could be administered safely every ten days, allowing a 
higher projected dose intensity of 52.5 mg/m2/week and 350 mg/m2/week, respectively. 
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Introduction 
The use of systemic chemotherapy has not resulted in a major improvement in the 
outcome of patients with disseminated breast cancer. Although the majority of 
patients will experience an initial response or stabilization of the disease on various 
combination chemotherapy regimens, relapses will often occur within one year and 
the median survival after start of treatment is limited to two years.1,2 Attempts to 
improve these results by increasing the dose of chemotherapy has met only limited 
success, mainly due to profound myelosuppression. Hematopoietic growth factors 
offer an opportunity to overcome this problem3-7, but whether this will lead to better 
results remains to be determined. Cyclophosphamide and the anthracycline 
doxorubicin are the most active single agents in the first line treatment of advanced 
breast cancer, producing an overall response of 36% and 43%, respectively. Since 
Canellos' report of the superior efficacy of combination chemotherapy over single-
agent chemotherapy, these drugs are mostly given in combination.8 4'-Epi-doxorubicin 
(epirubicin) is a synthetic doxorubicin analogue, which is reported to produce similar 
activity as Doxorubicin at equimolar doses with decreased overall toxicity, in particular 
cardiotoxicity.9 Several studies suggest a significant dose-response relationship for 
anthracyclines in breast cancer.10-14 High dose cyclophosphamide has been shown to 
induce responses in a variety of relapsed or refractory malignancies and has been part 
of double-alkylator therapy with autologous bone marrow rescue in advanced breast 
cancer.15,16 These clinical findings suggest a dose-response relationship for 
cyclophosphamide and anthracyclines in human cancers, including breast cancer, 
making them of interest to be combined with hematopoietic growth factors. 
Hematopoietic growth factors can be used to obtain increased dose-intensity by 
allowing a higher dose of chemotherapy per course (dose-escalation) or by allowing a 
shortening of interval between courses (dose-dense). Both approaches may lead to a 
higher dose-intensity, but their biological effect and thereby clinical relevance may be 
quite different as has been pointed out by Henderson in his review on the dose-
intensity phenomenon in breast cancer.17 The relative merits of these two approaches 
have not been studied systematically. 
Epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 every three weeks is an active 
and frequently used chemotherapy regimen in (locally) advanced breast cancer. In an 
EORTC pilot study of (locally) advanced breast cancer, Piccart (personal 
communication) succeeded in escalation of the epirubicin/cyclophosphamide 
combination. In her selected patient group the maximal tolerable dose of a 3-week 
schedule epirubicin and cyclophosphamide, without hematopoietic growth factors, 
was 120 mg/m2 and 830 mg/m2, respectively. 
Based on these considerations we performed a randomized study with the aim to 
compare the maximal dose intensity of epirubicin and cyclophosphamide with the 
support of the hematopoietic growth factor Granulocyte-Colony Stimulating Factor 
(G-CSF), if given with fixed doses and decreasing intervals or with increasing doses and 
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fixed intervals. The second aim was to assess the safety profiles of these intensified 
schedules. 
Patients and methods 
Patient selection 
Women with advanced breast cancer, between 18-70 years of age, an Eastern 
Cooperative Oncology Group (ECOG) performance status less than three and no prior 
chemotherapy for metastatic disease, were eligible. Patients may have received prior 
hormonal therapy for metastatic disease, adjuvant chemotherapy with/or without 
anthracyclines, if at entry the prior cumulative dose of doxorubicin or epirubicin did 
not exceed 300 mg/m2 and 450 mg/m2 respectively. Prior radiotherapy, provided 
involving not more than 25% of red bone marrow and provided patients had 
recovered from the acute toxicities, was allowed. Patients with symptomatic angina 
pectoris, congestive heart failure, myocardial infarction within the last year, 
irreversible arrhythmias or uncontrolled arterial hypertension were excluded. Patients 
with CNS involvement, psychologic problems impairing follow-up, neutrophils less 
than 2.000/μl or platelets less than 100.000/μl, or serum creatinine level more than 
1.2 mg/dl or serum total bilirubine more than 1.5 mg/dl were also ineligible. Informed 
consent was obtained before patients were included in the trial. Randomization was 
by a telephone to the study-coordinator and was stratified by hospital. 
Treatment plan 
This two-armed randomized schedule finding study was conducted in 6 hospitals in 
the Netherlands. In the study G-CSF (Filgrastim, Amgen Inc. Thousand Oaks, California, 
USA) was used.  
Arm 1 consisted of increasing doses of epirubicin and cyclophosphamide at day 1, 
with a fixed interval of 21 days. The G-CSF (300 μgm for patients ≤70 kg and 480 μgm 
for patients >70 kg) was administered subcutaneously daily from day 2 till neutrophil 
recovery (>1.500/μl). The starting dose level of epirubicin/cyclophosphamide was 
140/800 mg/m2, and it was planned to increase the dose to 160/900 mg/m2 and 
180/1000 mg/m2, respectively. Due to severe toxicity (see results) this first level had 
to be closed early and subsequently a lower dose 120/700 mg/m2 was studied (Table 
2.1). 
Arm 2 consisted of shortening intervals with fixed doses of epirubicin 75 mg/m2 and 
cyclophosphamide 500 mg/m2 on day 1, with the G-CSF administered from day 2 till 
the day before next cycle. The starting interval was 14 days, and was planned to be 
shortened to 12 and 10 days, respectively (Table 2.1). 
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A cohort of at least six patients was studied at each interval/dose and changes in 
intervals or doses were done in subsequent cohorts of patients. No progressive dose 
escalation or interval shortening was allowed in the same patient. 
For this study specific Dose-Intensity Limiting Criteria (DILC, see Table 2.2) had been 
defined. Proceeding to the next, more intensified, level took place after completing 
the previous cohort of patients and only if less than 50% of these patients had 
experienced a DILC during the first three courses. 
 
Table 2.1 Treatment schedule. 
Arm/Level Epirubicin/Cyclophosphamide 
(mg/m2) 
Interval 
days 
No. of 
Patients 
Arm 1    
  Level 1.0  120 / 700  21 10 
  Level 1.1  140 / 800  21   3 
  Level 1.2  160 / 900  21 - 
  Level 1.3  180 / 1.000  21 - 
Arm 2    
  Level 2.1    75 / 500  14   9 
  Level 2.2    75 / 500  12   7 
  Level 2.3    75 / 500  10 12 
  Level 2.4    75 / 500    8   8 
 
 
Table 2.2 Dose-intensity limiting criteria (DILC). 
1 WHO grade 3 or 4 stomatitis 
2 Neutropenia grade 4: neutrophil count <500/µl for a period of more than seven days 
3 Febrile neutropenia: neutrophil count <500/μl and fever 
4 Thrombocytopenia grade 4: platelet <25.000/μl for more than 4 days 
5 Delay of chemotherapy due to incomplete recovery on the day of scheduled therapy: 
  Hematological: neutrophil count <2.000/μl and/or platelet <100.000/µl 
  Persistence of non-hematological side effects of WHO grade 2 or more (excluding alopecia and 
anticipatory nausea and vomiting) 
6 Cardiotoxicity, defined by development of clinical cardiac failure or an absolute decrease in resting 
nuclear LVEF either ≥20% (EF absolute units) from baseline to a value above 50% or ≥10% (EF 
absolute units) to a value below 50% 
7 Any other WHO grade 4 non-hematological toxicity 
 
 
The patients had to complete a minimum of three cycles before considering to take 
them off study, except in case of disease progression, cardiac toxicity, unacceptable 
toxicity precluding further therapy or patients' refusal to continue treatment. Patients 
with an objective response or stable disease and without a DILC in the first three 
cycles continued the treatment at the same dose level they had entered the study as 
long as this was in the best interest of the patient. 
Epirubicin and cyclophosphamide were administered by intravenous bolus injections. 
In both arms the neutrophils (>2.000/μl) and platelets (>100.000/μl) counts had to be 
recovered on the day of chemotherapy administration. In the first three cycles no 
Thesis_Lalisang_v01.pdf
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dose adjustments on the basis of myelosuppression were allowed. In case of 
incomplete hematological recovery treatment was delayed and patients were scored 
as meeting a DILC. In case of WHO grade 3-4 stomatitis, diarrhea, vomiting during 
adequate antiemetic protection, or febrile neutropenia the doses of epirubicin and 
cyclophosphamide were reduced, and the patient was again scored as meeting a DILC. 
No concomitant other chemotherapy or hormonal therapy was permitted. 
Prophylactic antibiotic therapy, also after a period of febrile neutropenia, was left to 
the discretion of the investigator. 
Patients were transfused when necessary to maintain a platelet count more than 
15.000/μl and hemoglobin level more than 8.0 g/dl. 
To express the dose-intensity of the treatments two equations were used. The 
Delivered Dose-Intensity (DDI) is defined as the actual given dose per m2 per week 
during the first three protocol cycles of treatment and the Maximum Tolerated Dose-
Intensity (MTDI) is the dose per m2 per week during the first three cycles of protocol 
treatment, that was found the maximum that could be tolerated. 
Pretreatment and follow-up evaluation 
Clinical staging was performed in all patients and included a complete history and 
physical examination with tumor measurements (if possible). Complete blood cell 
counts with differential and platelet counts were performed initially and repeated 
twice weekly after the start of therapy. A biochemical profile was assessed before 
each cycle. A baseline measurement of resting LVEF by multi-gated nuclear scan 
(MUGA) was requested, but was obligatory in patients with prior anthracycline 
containing adjuvant chemotherapy. Follow-up MUGA scan was requested in case of 
clinical signs of congestive heart failure, if patient went off study or at a cumulative 
dose of 500 mg/m2 epirubicin, at 800 mg/m2 and subsequently before each next 
treatment course thereafter. Staging procedures consisted of chest X-rays, bone 
scintigraphy followed by X-ray of suspected areas, and, if indicated, ultrasound and/or 
computer tomography scans of suspected areas. Tumor evaluation was repeated after 
three and six cycles, at the end of treatment or as clinically indicated and evaluated 
according to UICC-criteria.18 Toxicity of both regimens was assessed after each course 
according to WHO grading criteria18 except for neutropenia, thrombocytopenia, 
febrile neutropenia and cardiotoxicity for which adjusted criteria were applied (DILC 2, 
3, 4 and 6; see Table 2.2). 
Results 
Patient characteristics 
Fifty-three eligible patients were entered, four patients were found to be not 
evaluable, three patients because of an incorrect dosing of Cyclophosphamide and 
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one because of incorrect G-CSF administration. Therefore, 49 patients were fully 
assessable for the present report. The characteristics of these 49 patients are shown 
in Table 2.3. These 49 patients underwent 197 cycles according protocol until DILC, 
progression or when stopping treatment was in best interest of patient. After meeting 
a DILC several patients continued the epirubicin/cyclophosphamide treatment with an 
adapted dose or schedule. 
Initial DILC's in the first three cycles (see Table 2.4). 
 
Table 2.3 Patient characteristics. 
Characteristics No. of patients  % 
Eligible / assessable 49   
Median age, years  50  
    Range  31 – 68  
Mean ECOG performance status  1  
    Range  0 - 2  
Locally advanced   1   
Metastatic 48   
Adjuvant chemotherapy 11   
Site of disease    
    Bone 33  69 
    Visceral 25  52 
    Soft tissue 33  69 
No. of organs involved    
    Median  2  
   Range  1 - 5  
    1   8   
    2 24   
    3   8   
    4   4   
    5   4   
Overall response 35 / 47  74 
    Complete response   7 / 47  15 
    Partial response 28 / 47  60 
    Stable disease   7 / 47  15 
    Not measurable   2   
Arm 1 
In arm 1 at the start (level 1.1) epirubicin/cyclophosphamide 140/800 mg/m2 q 21 
days three patients were entered. All patients suffered febrile neutropenia and one of 
them also a stomatitis grade 3 after the first course; one patient also developed a 
WHO grade 4 thrombocytopenia. Because these first three patients of an intended 
cohort of six patients already met a DILC, this level was closed and a lower dose (level 
1.0) was tested. Ten patients were tested on the level epirubicin/cyclophosphamide 
120/700 mg/m2 q 21 days, with a median delivered dose intensity for epirubicin of 40 
(37-41) mg/m2/week and for cyclophosphamide of 229 (216-244) mg/m2/week, 
respectively. Two patients encountered a DILC, febrile neutropenia in the first cycle. 
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Given the considerable level of toxicity seen with epirubicin/cyclophosphamide 
140/800 mg/m2 we decided not to test epirubicin/cyclophosphamide 130/750 mg/m2 
q 21 days but to consider epirubicin/cyclophosphamide 120/700 mg/m2 to be the 
MTD at 21 days interval (Table 2.4). This would mean a MTDI for epirubicin of 
40 mg/m2 and for cyclophosphamide of 233 mg/m2. 
 
Table 2.4 Epirubicin/cyclophosphamide + G-CSF initial DILC during the first 3 cycles  
 Epirubicin / Cyclophosphamide (mg/m2) 
 140/800 120/700 75/500 75/500 75/500 75/500 
Treatment interval (days) 21 21 14 12 10 8 
No. of patients   3 10   9   7 12 8 
Patients with DILC   3   2   0   1   4 7 
Initial DILC       
    ANC-recovery     1 C3 4 C1 3 C2 
    Platelet-recovery      1 C2
 b 
    Febrile Neutropenia 3 C1 2 C1   1 C1  
    Mucositis ≥WHO 3  1 C1 c      
    Nausea/vomitus ≥WHO 3     1 C2  
    Delay persistence ≥ WHO 2    1 C2 a   1 C2 a  
ANC, absolute neutrophil count; C1, cycle one; C2, cycle two; C3, cycle three. 
a Both patients had persistent WHO grade 2 stomatitis at the day of scheduled cycle 3; b One patient 
concurrent delayed platelet and absolute neutrophil count recovery at the day of scheduled cycle 3; c One 
patient concurrent febrile neutropenia and WHO grade 3 mucositis. 
Arm 2 
In arm 2 of decreasing intervals with fixed doses of epirubicin and cyclophosphamide 
75/500 mg/m2, in the 14 days (level 2.1) and 12 days (level 2.2) interval none out of 
nine patients and one out of seven patients met a DILC during the first three cycles 
respectively. The patient in the 12 days interval meeting a DILC needed delay due to 
stomatitis WHO grade 2 on the day of scheduled third cycle. At the 10 days (level 2.1) 
interval four patients out of 12 had a DILC. Febrile neutropenia occurred in one 
patient during the first cycle, and one patient needed delay of the third cycle due to 
persistence of stomatitis grade 2 at the day of planned chemotherapy. One patient 
showed a delayed neutrophil recovery after the third cycle and in the fourth patient 
nausea/vomitus WHO grade 3 after the second cycle was observed. The median 
delivered dose-intensity for the first three cycles was: epirubicin 49 
(31-58) mg/m2/week and cyclophosphamide 327 (207-384) mg/m2/week. Because still 
less than 50% of the patients had a DILC, an additional level with a eight days interval 
(level 2.4) was tested. The 8-day interval was too short, seven out of eight patients 
met a DILC during the first three cycles, making this level not feasible based on the 
predefined criteria. The initial DILC's in all these patients were a delay of the next 
cycle because of incomplete hematologic recovery: incomplete neutrophil recovery on 
the day of planned cycle 2 and cycle 3, four and two patients respectively. The 
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seventh patient had an incomplete neutrophil and platelet recovery on the day of 
planned cycle 3. 
Cumulative toxicity 
Patients were treated at their intended dose or interval level for three cycles or less if 
a DILC occurred. Although they were formally taken off study, many of those not 
having a DILC continued with additional courses. Since toxicity was monitored this 
allowed to obtain data on new or cumulative toxicity. 
Arm 1 
Eight of ten patients at the 120/700 mg/m2 level had no DILC in the first three courses. 
Six of them went on to complete at least six cycles without additional DILC's. The 
kinetics of ANC and platelet counts of these patients over six courses are shown in 
Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Epirubicin 120 mg/m2 and cyclophosphamide 700 mg/m2 plus G-CSF every 21 days; median 
values per day of consecutive chemotherapy cycles according to protocol: (A) neutrophils 
(x1,000/μl), (B) platelets (x1,000/μl)  
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Arm 2 
In the first cohort (14 days interval) no DILC's were observed during the first three 
courses. All (9) patients completed 45 cycles according to study protocol with a 
median of 5 per patient (range, 3-7). In one patient delay of the scheduled sixth cycle 
was necessary due to incomplete platelet recovery. In the 12 days interval six of seven 
patients had no DILC in the first three courses. They all went on with therapy to a 
median of 6 (range, 5-6) courses without any DILC. 
In the 10 days interval eight of twelve patients had no DILC in the first three courses. 
They all continued therapy to a median of 6 (range, 4-9) courses. Two of these eight 
patients had a DILC during subsequent treatment, one in the fourth cycle (could not 
tolerate physically the shorter intervals and also asymptomatic cardiotoxicity) and one 
in the sixth cycle (stomatitis grade 3). The single patient in 8 days interval without a 
DILC in the first three courses, could complete an additional three courses without a 
DILC. The kinetics of ANC and platelet counts in the patients with 14, 12 and 10 days 
interval not having DILC in the first three courses are shown in figure 2.2. It appears 
that there is no cumulative neutropenia and thrombocytopenia over six courses, even 
in the eight patients treated with 10 days interval. 
Transfusion of blood cells 
The intense treatment resulted in anemia and the need for packed red cell 
transfusions in the majority of patients. Data are shown in Table 2.5 for the separate 
dose or interval levels. It appears that most transfusions occurred in the patients 
receiving three additional cycles of therapy. Platelet transfusion was indicated in 3 out 
of 13 patients in the arm with dose escalation, but not in the interval shortening arm. 
 
Table 2.5 Transfusion of erythrocytes. 
 Dose escalation (mg/m2) Interval reduction (days) 
 140/180 120/700 14 12 10 8 
No. of patients 3 10 9 7 12 8 
Transfused cycle 1-3 2/3 03/10 1/9 1/7 02/12 2/8 
Transfused cycle 3+ 2/3 4/8 2/9 4/7 07/11 6/8 
Total patients transfused 2/3 04/10 2/9 5/7 08/12 6/8 
 
Cardiotoxicity 
In our study cardiac toxicity was defined as development of clinical cardiac failure or 
an absolute decrease in resting LVEF either ≥20% (EF absolute units) to a value above 
≥50% or ≥10% (EF absolute units) to a value below 50%. During the study period no 
clinical symptoms of congestive heart failure or ECG abnormalities were observed. 
Basal and follow-up nuclear MUGA LVEF's were available in 26 of 49 patients, making 
them evaluable for cardiotoxicity by ejection fraction. A pathological, decline in LVEF 
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as defined above was observed in three patients, all treated in the 10 or 8 days 
intervals. In the first patient follow-up MUGA scan eight days after the fifth course 
showed a decrease from baseline level 64% to 48%. The second patient was admitted 
three days after the third course with a collapse, dyspnoea, non neutropenic fever 
and severe anemia (4,5 gr/dl). ECG showed sinus tachycardia without further 
abnormalities. MUGA scan showed a LVEF decrease from baseline 64% to 40%. In the 
third patient the LVEF after the third cycle showed a decrease from 65% (baseline) to 
48%. Therefore, 3 out of 14 (21%) patients treated in the shorter intervals and 
evaluable for cardiotoxicity showed a pathological decline, according the DILC 
criterium. These 3 patients were not previously treated with chemotherapy, and the 
cumulative dose of Epirubicin at the time of this observation ranged from 225 to 
450 mg/m2. The follow-up LVEF's were performed between three and ten days after 
the last chemotherapy course. Additional follow-up LVEF measurements in the second 
patient (14 days later 53%), in the third patient (8 months later 62%) showed 
normalization in 2 out of these 3 patients; in the first patient no further 
measurements were available. However, six months later no cardiac clinical 
symptoms were present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Interval-shortening epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 plus G-CSF, 14- 
12-, and 10-day intervals. Median values per day of consecutive chemotherapy cycles 
according to protocol: (A) neutrophils (1,000/μl), (B) platelets (1,000/μl). 
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Response Rate 
Efficacy was not an aim of this study. However, formal UICC criteria were applied to 
the 47 patients with measurable disease. An objective response was observed in 34 
out of 46 (74%) patients with metastatic disease, complete response in seven and 
partial response in 27 patients, respectively. Stable disease was observed in seven 
patients. The single patient with locally advanced disease had a partial response. 
Discussion 
The aim of our study was to determine the maximal dose intensity of epirubicin in 
combination with cyclophosphamide in patients with metastatic breast cancer, 
supported by the hematopoietic growth factor G-CSF, but without hematopoietic 
stem cell support. Two approaches were studied: increasing the dose in individual 
cycles with a fixed interval and decreasing the interval with a fixed dose. 
With dose escalation of epirubicin and cyclophosphamide with G-CSF in a 3 week 
schedule a maximal tolerable dose of 120 mg/m2 and 700 mg/m2 respectively, was 
achieved. Dose limiting toxicity was febrile neutropenia. It was observed in two out 10 
patients at this dose level, but occurred in three out of three patients treated with 
140 mg/m2 epirubicin and 800 mg/m2 cyclophosphamide. Piccart investigated 
epirubicin/cyclophosphamide 120/830 mg/m2 with the addition of G-CSF in locally 
advanced and metastatic breast cancer in cohorts of decreasing intervals.7 The 
minimal tolerable interval was 14 days, with the G-CSF administered from day 2-13. 
Dose limiting toxicity was encountered in five out of 12 patients, 2 patients with 
severe non-hematologic toxicity (mucositis and skin toxicity), and 3 patients with 
febrile neutropenia. From our and Piccart's data it appears that 120-130 mg/m2 
epirubicin in combination with moderate dose (700-830 mg/m2) cyclophosphamide is 
the maximum tolerated dose. Although G-CSF will accelerate the recovery from the 
ANC nadir, this does not allow significant dose escalation as evidenced by our findings 
in the epirubicin/cyclophosphamide 140/800 mg/m2 cohort. The MTDI in our study 
was therefore set at 40 mg/m2/week of epirubicin and 233 mg/m2/week of 
cyclophosphamide. It remains unclear whether further escalation of the dose of this 
particular combination can be achieved by adding hematopoietic stem cell support. 
Shortening of intervals with epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 
with G-CSF support, permitted a minimal tolerable interval of 10 days, allowing a 
median delivered dose intensity for epirubicin of 49 mg/m2/week and 
cyclophosphamide 327 mg/m2/week and a MTDI of 52,5 mg/m2/week for epirubicin 
and of 350 mg/m2/week for cyclophosphamide. Therefore, reducing intervals with 
standard dose is more effective in increasing dose intensity than dose escalation with 
standard intervals. Some escalation of the dose of 75 mg/m2 epirubicin and 
500 mg/m2 cyclophosphamide per course may be possible making an even higher 
dose-intensity achievable. 
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An important aspect of studies on escalated dose intensities is whether this can be 
maintained over repeated cycles. Conceivably with intervals as short as 10 days and 
retreatment at the moment of rapid recovery the population of progenitor cells may 
be vulnerable to the repetitive cytotoxic insults and may become exhausted after a 
number of cycles. Although we have only data collected over six cycles, we have not 
observed signs of exhaustion. It may well be that in fact the treatment with G-CSF till 
24 hours before the next chemotherapy has protected progenitor cells by putting 
them out of cycle as has been suggested by Vadhan-Raj et al. using GM-CSF.19 Also 
thrombocytopenia has rarely been dose limiting, even after 6 cycles of 
epirubicin/cyclophosphamide at the 10 days interval. Further data on larger numbers 
of patients with even more cycles are needed to determine the absence of cumulative 
myelosuppression with certainty. 
We observed a clinically asymptomatic cardiotoxicity in 21% of patients treated with 
the shorter intervals, that appeared however reversible with longer follow-up. A 
possible explanation for the temporary pathologic decline may be the short interval 
between chemotherapy administration and the LVEF measurement, suggesting a 
reversible myocardial injury through free radicals induced by epirubicin and its toxic 
metabolites.20 This possibly more frequent cardiotoxicity needs further careful 
evaluation. 
Since Bronchud's initial report, applying doxorubicin in combination with G-CSF, 
several investigators have explored dose intensification with CSF's in the treatment of 
advanced breast cancer in phase I/II studies (Table 2.6).3,6,7,21-23 In different schedules 
and combinations maximal tolerable dose intensities of 55 mg/m2/week of epirubicin 
in combination with 350 mg/m2/week of cyclophosphamide could be reached. This is 
an increase of dose intensity from standard epirubicin/cyclophosphamide treatment 
with a factor 2,1. In these selected patients promising response rates, with a relatively 
high percentage of complete remissions, were achieved. From a study of 
anthracycline containing adjuvant therapy in breast cancer it is known that differences 
of a factor 2 may make a difference in outcome14. Whether this is also the case in 
metastatic breast cancer cannot be concluded from the present studies. 
 
Table 2.6 Dose-intensification with CSF support in metastatic beast cancer. 
First author Treatment Schedule    Response % 
and reference (mg/m2)   CSF OR cCR 
Bronchud3 D 120 every 12 days D 70 G-CSF 74 21 
Hoekman6 D/C 90/1,000 every 21 days D/C 30/333 GM-CSF 80 20 
Scinto21 E/C 120/600 every 14 days E/C 60/300 G-CSF 86 50 
Lalisang E/C 75/500 every 10 days E/C 52.5/350 G-CSF 74 15 
Piccart7 E/C 120/830 every 14 days E/C 60/415 G-CSF 87 20 
Marangalo22 E 150 every 15 days E 70 G-CSF - - 
Ardizonni23 F/E/C 600/60/600 every 16 days F/E/C 260/26/260 GM-CSF - - 
GM-CSF = granulocyte-macrophage colony-stimulating factor, D = doxorubicin, E = epirubicin,  
C = cyclophosphamide, F = 5-fluoro-uracil 
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The aim of dose intensification is to increase the dose of treatment to the limit of 
normal tissue tolerance for the drugs used, with the intention of maximizing anti 
tumor efficacy. Dose intensity, dose size and cumulative dose may each have 
important but different effects on outcome. According to the analysis of Goldie and 
Coldman the major effect of high dose intensity is a more rapid and effective 
eradication of sensitive tumor cells and the dose size the most important factor in 
reducing the chance of developing resistant cells.24,25 
Norton showed that a Gompertzian growth model precisely fitted in the growth 
curves of breast cancer.26,27 In this model, when a patient with advanced breast cancer 
is treated and the tumor mass is large, its growth fraction is low and the fraction of 
cells killed is low. Shortening of intervals ("dose-dense chemotherapy") may be 
important to overcome the cytokinetic resistance of tumors, by killing chemosensitive 
cells and recruiting regrowth of dormant cells, which will be killed by the subsequent 
cycle.28 Therefore on theoretical grounds, treatment of advanced breast cancer may 
start with short repetitive cycles of effective dose (dose-dense) chemotherapy, 
followed by increased dose size (dose-escalated) chemotherapy. 
In conclusion, with the addition of G-CSF, shortening of intervals between standard 
doses of chemotherapy in comparison with increasing doses and fixed intervals, 
seems to be an effective method of dose intensification, allowing a projected dose 
intensity of 52,5 mg/m2/week of epirubicin in combination with 350 mg/m2/week of 
cyclophosphamide. The efficacy and clinical relevance of this approach, that on 
theoretical grounds may be particularly attractive in the early phase of the treatment 
of patients with metastatic breast cancer, must be demonstrated in further studies. 
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Summary 
Background 
Anthracyclines and taxanes are very effective drugs in the treatment of advanced breast cancer. With 
G-CSF support, the dose-intensity of this combination can be increased by reducing the interval between 
chemotherapy cycles, the so-called "shortening of cycle time". 
 
Patients and Methods 
We treated 36 patients with advanced breast cancer in a multicenter phase I/II study. The treatment 
regimen consisted of epirubicin 75 mg/m2 followed by paclitaxel 135 mg/m2 (three hours) in combination 
with G-CSF (5 μg/kg). At least six patients were treated in each cohort and were evaluated over the first 
three cycles. 
 
Results 
Starting at an interval of 14 days in subsequent cohorts of patients the interval could be shortened to ten 
days. The eight-days interval was not feasible mainly due to incomplete neutrophil recovery at the day of 
the next scheduled cycle. In the cohort of ten days interval it was feasible to increase the paclitaxel dose to 
175 mg/m2. The hematological and non-hematological toxicity was relatively mild. No cumulative 
myelosuppression was observed over at least three consecutive cycles. 
 
Conclusion 
In combination with G-CSF, epirubicin 75 mg/m2 and paclitaxel 175 mg/m2 could be safely administered 
every ten days over at least three cycles, enabling a dose intensity of 52 and 122 mg/m2/week, 
respectively. 
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Introduction 
Anthracyclines and taxanes belong to the most active single agents in advanced breast 
cancer. Paclitaxel is highly active and lacks cross-resistance with other drugs 
commonly used in breast cancer treatment.1,2 Studies of single agent paclitaxel 
demonstrate that leucopenia is frequent and dose limiting in all schedules (3-, 6-, 
24-hour infusion) evaluated. Randomized trials evaluating the 3- and/or 24-hour 
schedules, each with two paclitaxel doses of 135 and 175 mg/m2, have revealed that 
neutropenia is dose- and schedule-dependent, without apparent difference in 
efficacy.3,4,5 The optimal therapeutic schedule of paclitaxel is still unknown and on 
practical grounds, the short infusion over three hours is safe, convenient and 
effective.6 
Paclitaxel at longer infusion rate (≥24 hours) has been given in combination with 
doxorubicin. The maximal tolerable dose (MTD) and toxicities (primarily mucositis and 
neutropenia) of this combination appear to depend on the sequence and infusion 
duration of the two drugs.7,8,9 In a study of escalating doses paclitaxel (3-hr infusion) in 
combination with fixed dose of doxorubicin (60 mg/m2 iv bolus) in a 3 weekly 
schedule, mucositis, long lasting grade 4 and febrile neutropenia defined the MTD of 
paclitaxel at 200 mg/m2, and was not sequence dependent. This regimen was very 
effective in chemotherapy-naive breast cancer patients, but at the cost of 
considerable increased cardiotoxicity.10,11 4'-Epi-doxorubicin (epirubicin) is a synthetic 
doxorubicin analogue, with similar activity but decreased toxicity, in particular 
cardiotoxicity.12 It may therefore be an attractive substitute for doxorubicin in 
combination with taxanes. 
Granulocyte colony stimulating factor (G-CSF) can be used to prevent neutropenia and 
to obtain increased dose-intensity by allowing a higher dose of chemotherapy per 
cycle (dose-escalation) or by allowing a shortening of interval between cycles (dose-
dense). Both approaches may lead to a higher dose-intensity, but their biological 
effect and clinical relevance may be quite different.13 These two approaches were 
investigated by our group in the treatment of metastatic breast cancer with epirubicin 
and cyclophosphamide. We concluded that with the addition of G-CSF interval 
reduction safely permitted a higher dose-intensity than dose escalation.14 Based on 
these results we started a study with the aim of increasing the dose-intensity of the 
epirubicin and paclitaxel combination by shortening of the cycle time. We intended to 
define the minimal tolerable interval of epirubicin 75 mg/m2 (iv bolus) followed by 
paclitaxel 135 mg/m2 (3-hour infusion) in combination with G-CSF support. The 
second aim was to assess the safety profile of this approach. 
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Materials and methods 
Patient selection 
Women with advanced breast cancer were accrued in this multi-centre open-label 
schedule finding study. The study protocol was approved by the institutional review 
boards of the participating hospitals, and patients had to give informed consent. 
Criteria for inclusion were as follows: histological proof of breast cancer; age 18 to 
70 years; performance status 0 to 2 (Eastern Cooperative Oncology Group [ECOG] 
scale), neutrophil count ≥2,000/μl and platelet count ≥100,000/μL; adequate function 
tests for liver (bilirubin level <1.5 mg/dl and transaminase levels <3 times upper limit 
of normal) and kidneys (serum creatinine level <1.2 mg/dl); no prior chemotherapy for 
metastatic disease; prior adjuvant chemotherapy allowed, if interval last 
chemotherapy cycle ≥1 year and at entry cumulative dose of doxorubicin ≤300 mg/m2 
and epirubicin ≤450 mg/m2; prior radiotherapy involving ≤25% of red bone marrow; 
LVEF by multigated isotope cardiography (MUGA-scan) ≥50% and without 
symptomatic cardiovascular disease; no central nervous system involvement. 
Treatment Plan 
In this schedule-finding study, the epirubicin (Pharmacia & Upjohn, Milan, Italy), 
paclitaxel (Taxol, Bristol-Myers Squibb Pharmaceuticals, Princeton, NJ) as well as 
R-metHuG-CSF (Filgrastim, Amgen Inc. Thousands Oaks, CA) dose was kept constant, 
and four intercyclic intervals were foreseen. The starting interval of 14 days, was 
planned to be decreased to 12, 10 and 8 days, respectively. To prevent 
hypersensitivity reactions due to paclitaxel formulated in cremophor EL a routine 
premedication regimen was adopted: oral or intravenous dexamethason 20 mg (6 and 
12 hours pre-treatment); clemastine 2 mg and ranitidine 50 mg both intravenously 
30-60 minutes before paclitaxel administration. Epirubicin was given as a short I.V. 
infusion on day 1 at a fixed dose of 75 mg/m2. Paclitaxel at a dose of 135 mg/m2 was 
administered by a 3-hour infusion, starting five minutes after epirubicin 
administration. G-CSF (300 μgm for patients ≤70 kg and 480 μgm for patients >70 kg) 
was administered once daily on all days except the days of chemotherapy. 
A cohort of at least six patients was studied at each interval. The neutrophil 
(≥2,000/μl) and platelet (≥100,000/μl) counts had to be recovered on the day of 
scheduled chemotherapy.  
For this study specific Dose-Intensity Limiting Criteria (DILC, see Table 3.1) had been 
defined. Proceeding to the next, shorter interval level was done only after completion 
of the previous cohort and if less than 50% of these patients had experienced a DILC 
during the first three courses. In case of incomplete hematological recovery treatment 
was delayed. Concomitant hormonal therapy or prophylactic antibiotic therapy was 
not allowed. Patients were transfused when necessary to maintain a platelet count of 
≥15,000/μl and hemoglobin level ≥8.0 g/dl.  
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The patients had to complete a minimum of three cycles, except in case one of the 
following events occurred: disease progression, DILC, any other unacceptable toxicity 
precluding further therapy or patients' refusal to continue treatment. After 
completion of the first three cycles further therapy was left at the discretion of the 
investigator. 
As the eight-day interval appeared to be not feasible (see results) a new cohort was 
tested in the 10-day interval with a higher paclitaxel dose of 175 mg/m2. 
The MTD for this study was defined as the maximum dose that resulted in less than 
50% instances of DILC’s among treated patients in each cohort. To express the dose-
intensity of the treatment the equation, Delivered Dose-Intensity (DDI): the actually 
given dose per m2 per week during the first three protocol cycles of treatment, was 
used. 
 
Table 3.1 Dose-intensity Limiting Criteria (DILC). 
1 Any WHO grade 3 or 4 non-hematological toxicity 
2 Neutropenia grade 4: neutrophil count <500/μl for a period of more than 7 days 
3 Febrile neutropenia: neutrophil count <500/μl and fever 
4 Thrombocytopenia grade 4: platelet count <25.000/ul for more than 4 days 
5 Delay of chemotherapy due to incomplete recovery on the day of scheduled therapy: 
 Hematological: neutrophil count <2.000/μl and/or platelet count <100.000/μl 
 Persistence of non-hematological side effects of WHO grade 2 or more (excluding alopecia and 
anticipatory nausea and vomiting) 
6 Cardiotoxicity, defined by development of clinical cardiac failure or an absolute decrease in MUGA 
LVEF either ≥20% (EF absolute units) from baseline to a value above 50% or ≥10% (EF absolute units) 
to a value below 50% 
 
Pretreatment and follow-up evaluation 
All patients were initially evaluated with a history, physical examination, complete 
blood cell count, liver and kidney function tests, ECG and LVEF MUGA scan, chest x-ray 
and bone scan. If indicated, x-ray studies of selected osseous segments, ultrasound 
and/or computer tomography scans of suspected areas, with tumor measurements (if 
possible) was performed. Complete blood cell count  was repeated twice weekly and a 
biochemical profile was assessed before each cycle. Follow-up LVEF MUGA scan was 
requested after each three cycles, in case of clinical signs of congestive heart failure, if 
patients went off study or at a cumulative dose of 500 mg/m2 epirubicin, at 
800 mg/m2 and subsequently before each additional treatment course thereafter. In 
our study cardiac toxicity was defined as development of clinical cardiac failure and/or 
an absolute decrease in resting LVEF either ≥20% (EF absolute units) from baseline to 
a value above 50% or ≥10% to a value below 50%. 
Tumor evaluation was repeated after each three cycles, at the end of treatment or as 
clinically indicated and evaluated according to UICC-criteria.15 Toxicity was assessed 
after each course according to WHO grading criteria15 except for neutropenia, 
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thrombocytopenia, febrile neutropenia and cardiotoxicity for which adjusted criteria 
were applied (see Table 3.1). 
Results 
Patient Characteristics 
Forty-one eligible patients were entered, and five patients were found to be not 
evaluable. In the 8-day interval four patients (protocol violations after cycle 1 [two 
patients] and central venous line complications [two patients]) and in the 10-day 
interval with paclitaxel 175 mg/m2 one patient (too low G-CSF dose). Therefore, 36 
patients were fully assessable for the present report. The characteristics of these 36 
patients are shown in Table 3.2. These 36 patients received 131 cycles according to 
the protocol until DILC or protocol completion. An additional 71 cycles were 
administered off protocol with longer intervals in 21 patients. 
 
Table 3.2 Patient characteristics. 
Eligible/evaluable 36 
Median age (range)  51 (24-68) 
Performance ECOG 0/1/2 14/18/4 
Adjuvant chemotherapy 14 
    Including anthracyclines   5 
Previous chest/breast irradiation 28 
Sites of disease in patients (% of all patients)  
    Bone 64% 
    Soft tissue 81% 
    Lung 36% 
    Liver 47% 
    Lung and/or liver 61% 
No. of organs involved  
    Median (range)  2 (1-5) 
 
Initial dose-intensity limiting criteria (DILC's) in the first three 
consecutive cycles 
In this study analyzing shortening of intervals with fixed doses of epirubicin and 
paclitaxel 75/135 mg/m2, six patients were entered at the starting interval of 14 days. 
One patient encountered a DILC: an incomplete platelet recovery was observed at 
scheduled cycle 2 (Table 3.3). At the 12-day interval one out of eight patients met a 
DILC: after the third cycle this patient developed nausea/vomitus WHO grade 3. In the 
10 days interval one out of 10 patients had a DILC: after the third cycle an incomplete 
neutrophil recovery was observed. At the eight-day interval four out of six patients 
met a DILC during the first three cycles, making this interval not feasible based on the 
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predefined criteria. The initial DILC's were: incomplete neutrophil recovery at 
scheduled cycle 2 in three patients and combined febrile neutropenia and mucositis 
WHO grade 3 after cycle 2 in the fourth patient. Ten days was the shortest feasible 
interval for epirubicin/paclitaxel 75/135 mg/m2 with G-CSF and the median DDI for 
the first three cycles was 52 (range 49-56) mg/m2/week and 94 (range 88-100) 
mg/m2/week, respectively. 
To investigate whether in the 10 days interval the dose of paclitaxel could be 
increased, epirubicin/paclitaxel 75/175 mg/m2 was tested in this 10 days interval. Two 
out of six patients encountered a DILC, transient asymptomatic pathologic decrease in 
cardiac LVEF after the third course, and infection (pneumonia) grade 2 at scheduled 
cycle four, respectively. The median DDI in the first three cycles was epirubicin 52 
(52-53) mg/m2/week and paclitaxel 123 (117-126) mg/m2/week. 
 
Table 3.3 Epirubicin/Paclitaxel + G-CSF; Initial Dose-intensity Limiting Criteria (DILC's) in the first three 
cycles 
Dose EP mg/m-2 
Interval days 
75/135 
14 
75/135 
12 
75/135 
10 
75/135 
8 
75/175 
10 
Evaluable patients 
Patient(s) with DILC 
  6 
  1 
  8 
  1 
10 
  1 
6 
4 
  6 
  2 
DILC 
   ANC-recovery 
   Platelet-recovery 
   Febrile neutropenia 
   Mucositis  grade ≥3 
   Nausea/vomitus grade ≥3 
   Infection  
   Cardiotoxicity  
 
 
  1 
 
 
 
 
  1 
 
 
 
 
 
  1 
 
  1 
 
3 
 
  1 a 
  1 a 
 
 
 
 
 
 
  1 
  1 
a One patient with concurrent febrile neutropenia and mucositis grade 3 after cycle 2. 
 
Cumulative toxicity 
In the 14-day interval all five patients without a DILC in the first three cycles continued 
at their scheduled interval for at least six cycles. In the 12-day interval seven out of 
eight patients continued the same chemotherapy combination after three protocol 
cycles, although only two patients at scheduled interval for a total of four cycles, all 
without additional toxicities. 
In the 10 day interval three out of ten patients continued scheduled treatment for a 
total of four (two patients) and nine (one patient) cycles, respectively. However the 
latter needed delay of cycle seven for five days because of an intercurrent periodontal 
infection and subsequently continued scheduled treatment. The single patient with an 
incomplete neutrophil recovery after cycle three, encountered again an incomplete 
neutrophil and platelet recovery after cycle four and five, and developed a reversible 
peripheral neuropathy grade 3 after cycle six. In the 8 day interval the two patients 
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without a DILC in the initial three cycles continued the scheduled interval for a total of 
five (stomatitis and infectious tonsillitis grade 3) and six cycles, respectively. The three 
patients with an initial incomplete neutrophil recovery, encountered the same DILC in 
additional cycles. The patient with a febrile neutropenia and stomatitis grade 3 after 
the second cycle in addition developed pulmonary embolism, and stopped protocol 
chemotherapy. In the 10 days interval epirubicin/paclitaxel 75/175 mg/m2 only one 
patient continued scheduled treatment for 6 cycles. The kinetics of neutrophil and 
platelet counts for the patients in the various intervals are shown in Figure 3.1. The 
non-hematological toxicities were generally mild and are displayed in Table 3.4. One 
patient encountered a hypersensitivity reaction WHO grade 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Interval shortening of epirubicin and paclitaxel plus G-CSF. Median values per day and range 
of values at the day of next scheduled cycle, of consecutive chemotherapy cycles according to 
protocol: (A) neutrophils (x 1000/μl), (B) platelets (x 1000/μl). 
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Table 3.4 Number of patients (percentage) encountering non-hematological toxicities (WHO-grading) 
for all cycles with epirubicin and paclitaxel with G-CSF support. 
WHO 
grading 
Nausea/ 
Vomitus 
Diarrhea Stomatitis Neurotoxicity Myalgia Infection Skin 
1 12 (32%) 3 (8%)   8 (22%)   9 (24%) 10 (27%) 0 0 
2 12 (32%)   5 (14%)   8 (22%) 3 (8%)   7 (19%) 2 (5%) 3 (8%) 
3 1 (3%)       0 3 (8%) 1 (3%) 1 (3%) 2 (5%)    0 
4       0       0      0           0       0       0    0 
 
Transfusion of bloodproducts 
In this dose dense schedule during the first 3 cycles red blood cell (RBC) transfusions 
were needed in five patients. Most transfusions occurred in the patients receiving 
more than three cycles (14 out 27 patients). Platelet transfusions were not given. 
Cardiotoxicity 
A total of 98 MUGA scans were performed; basal and follow-up scans were available 
in 35 of 36 patients, making them evaluable for cardiotoxicity by ejection fraction. A 
pathological decline in LVEF, as defined earlier, was observed in two (6%) patients 
after the first three cycles, all without previous anthracycline containing adjuvant 
chemotherapy. In the 14-day interval the patient with a delayed platelet recovery 
after the first cycle, received cycle two after platelet recovery, which was complicated 
by severe dyspnea and anemia, with a transient decrease in LVEF (63% → 49%). On 
physical examination, chest X-ray and ECG no signs of congestive heart failure were 
observed. After RBC transfusion patient recovered and a control LVEF showed 
normalization (62%). This patient continued scheduled treatment for an additional 
three cycles, without further signs of cardiac failure. A short interval (one day) 
between the end of radiotherapy on the lumbar spine and start of study treatment 
may explain these transient DILC's. In the second patient (10 day interval EP 
75/175 mg/m2) after 3 cycles an asymptomatic change in LVEF (60% → 49%) was 
observed. Patient continued with three cycles of epirubicin/cyclophosphamide (EC) 
with follow-up LVEF's of 53% (after first EC), 59% (after third EC) and 65% (three 
months after third EC), respectively. From 20 patients cardiac evaluation is available 
with a cumulative epirubicin dose of ≥450 mg/m2; median baseline LVEF 60% (range 
50%-72%) → 58% (range 30%-77%). One patient in the 14 days interval continued, 
after 6 protocol cycles, the same regimen with a 21 days interval and developed 
congestive heart failure with a LVEF of 30% after cycle 13 (cumulative dose epirubicin 
975 mg/m2). The single patient with a DILC in the 10 day interval at a dose of 
75/135 mg/m2, developed symptomatic ventricular extrasystoles after cycle 3, 
without a decrease in LVEF, and continued treatment for a total of 6 cycles. 
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Response rate 
Although efficacy was not an aim of this study, formal UICC criteria were applied to 
the 29 patients with measurable disease. After three cycles, i.e. evaluation 20-42 days 
after the start of the study treatment, already an objective response (all partial) was 
observed in 17 out of 29 patients (55%, 95% CI 41-77%), and there were no patients 
with progressive disease. Nineteen patients (stable disease 11, partial response 6 and 
1 mixed response) continued protocol treatment with an interval of ≤14 days for a 
median number of six cycles (range 4-9) whereby six additional patients reached a 
partial response and two partial responders reached a complete remission. The 
median interval between the start of therapy and the first observation of an objective 
clinical response was five weeks (range 3-12 weeks). The best response for the total 
study group was 79% (95% CI 65-94%). 
Discussion 
The aim of our study was to determine the maximal dose intensity of epirubicin in 
combination with paclitaxel in a dose dense schedule, supported by G-CSF. With a 
regimen consisting of epirubicin 75 mg/m2 and paclitaxel 135 mg/m2 an interval of 10 
days was feasible, allowing a median DDI of 52 mg/m2/week for epirubicin and 
94 mg/m2/week for paclitaxel, respectively. In the 10 day interval it was feasible to 
increase the paclitaxel dose to 175 mg/m2 enabling a median DDI of 123 mg/m2/week 
for paclitaxel in combination with 52 mg/m2/week of epirubicin. The treatment-
schedule related toxicity was relatively mild. Nine out 36 patients developed a DILC in 
the first 3 cycles. Initial DILC's were incomplete hematological recovery at the day of 
scheduled cycle in five, febrile neutropenia in one and non-hematological in the 
remaining three patients, respectively. 
An important aspect of studies on escalated dose intensities is whether this can be 
maintained over repeated cycles. Conceivably with intervals as short as 10 days and 
retreatment at the moment of rapid recovery, the population of progenitor cells may 
be vulnerable to the repetitive cytotoxic insults and may become exhausted after a 
number of cycles. Although most data were collected over 3 cycles, we have not 
observed signs of exhaustion, also not in the small number of patients treated up to 
six cycles. It may well be treatment with G-CSF up to the day before the next 
chemotherapy has protected progenitor cells by putting them out of cycles as has 
been observed with GM-CSF.16 In a study of the epirubicin-paclitaxel combination in a 
21 days interval without G-CSF the neutrophil-nadir occurs at day 12 and the median 
neutropenia grade 4 duration was 3 days.17 In our study, with G-CSF, the neutrophil-
nadir was reached earlier, at day 8, was of very short duration, and was less 
pronounced in each consecutive cycle. G-CSF administered on all days, with the 
exception of the day of chemotherapy, fastened the neutrophil recovery after each 
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chemotherapy course, but may also have had a pre-emptive effect on each 
consecutive cycle by expansion of the progenitor pool. However, this so-called pre-
emptive G-CSF effect was not observed earlier.18 Thrombocytopenia has not been 
dose limiting. Further data on larger numbers of patients with even more cycles are 
needed to determine the absence of cumulative myelosuppression with certainty. 
The MTD of the epirubicin and paclitaxel (3-hour) combination in a 21 days schedule 
without "prophylactic" hematopoietic growth factor as first line treatment in 
metastatic breast cancer has been investigated. The several MTD’s of this 
combination were 50/250 mg/m2, 60/175 mg/m2, 90/175 mg/m2 and 90/200 mg/m2, 
respectively. Dose limiting toxicities were primarily hematologic: severe neutropenia 
and febrile neutropenia.19-21 The DDI in the latter study is 30 mg/m2/week for 
epirubicin and 67 mg/m2/week for paclitaxel, which is considerable lower than our 
results of 52 and 122 mg/m2/week, respectively. In these three studies the objective 
response rates after at least 6 cycles were 44%, 68% (CR in 17%) and 84% (CR in 18%), 
respectively.19-21 These data suggest a dose-response relationship for epirubicin. In our 
study after three short interval cycles already a response rate of 53% was observed.  
The combination of paclitaxel (3-hrs) and bolus doxorubicin was very effective 
(83-95% overall response rate, 24-41% complete responses) in two single-center 
phase I/II studies with chemotherapy-naive patients.10,11 Six combination chemo-
therapy cycles were apparently sufficient to achieve at least a partial response (CR 
15%) in all responding patients. Continuous treatment with single-agent paclitaxel, 
significantly contributed to the final complete response rate of 41%.22 The difference 
in response rates between the epirubicin and doxorubicin studies may be explained by 
the considerable higher percentage of adjuvant chemotherapy pretreated patients in 
the epirubicin/paclitaxel combination studies. A recent multicenter randomized phase 
III study with doxorubicin 50 mg/m2 (bolus iv) and paclitaxel 150 mg/m2 (24-hours), 
reported a response rate of only 46%.23 
An important argument to investigate epirubicin in combination with paclitaxel, is to 
circumvent the increased cardiotoxicity of the doxorubicin/paclitaxel combination; 
after a median cumulative doxorubicin dose of 480 mg/m2, 50% of the patients had 
reductions of the cardiac left ventricular ejection fraction (LVEF) below the norm and 
20% of the patients developed a congestive heart failure.10,11 To prevent this excess in 
cardiotoxicity, the cumulative dose of doxorubicin in this combination needs to be 
limited to 360 mg/m2, which makes this regimen not applicable in doxorubicin 
adjuvant pretreated patients.24 In the epirubicin/paclitaxel combination studies 
cardiac toxicity was observed in 13% (all anthracycline pretreated), 1% and 8% of the 
patients, respectively.19-21 In the latter study a minimal median LVEF decrease 
(58%→56%) was observed after a cumulative epirubicin dose of >900 mg/m2.21 These 
data suggest less cardiotoxicity for the epirubicin/paclitaxel combination.  
Norton has shown that a Gompertzian growth model precisely fitted in the growth 
curves of breast cancer.24 In this model, when a patient with advanced breast cancer 
is treated, the tumor mass is large, its growth fraction is low and the fraction of cells 
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killed is low. Shortening of intervals with effective dose combination chemotherapy 
(dose dense) may be important to overcome the cytokinetic resistance of tumors, by 
killing chemosensitive cells and recruiting regrowth of dormant cells, which will be 
killed by the subsequent cycle. Therefore on theoretical grounds, treatment of 
advanced breast cancer may start with short repetitive cycles of effective dose (dose-
dense) chemotherapy, followed by increased dose size (dose-escalated) chemo-
therapy. 
In conclusion, with the addition of G-CSF, shortening of intervals of chemotherapy 
seems to be an effective method of dose intensification, allowing a dose intensity of 
52 mg/m2/week of epirubicin in combination with 122 mg/m2/week of paclitaxel. The 
efficacy and clinical relevance of this approach, is investigated now in a phase II study. 
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Abstract 
Background 
An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-
escalation) or by shortening the interval between cycles (dose-dense). 
 
Design 
This multicentre randomized phase II study assessed the efficacy and safety of two different approaches: 
epirubicin 110 mg/m2 combined with paclitaxel 200 mg/m2 every 21 days and epirubicin 75 mg/m2 
combined with paclitaxel 175 mg/m2 every 10 days, both supported with G-CSF. Patients with advanced 
breast cancer and without prior palliative chemotherapy were scheduled for 6 cycles. 
 
Results 
101 patients were evaluable for response and 106 patients for toxicity. Grade ≥3 toxicities occurred in 39% 
of patients in the dose-escalated arm and in 29% of the dose-dense arm, mainly febrile neutropenia, 
thrombocytopenia, neurotoxicity and (asymptomatic) cardiotoxicity. The median delivered cumulative 
doses for epirubicin/paclitaxel were 656/1194 mg/m2 and 448/1045 mg/m2, treatment durations were 126 
and 61 days, and delivered dose intensities were 36/67 mg/m2/week and 51/120 mg/m2/week for the 
dose-escalated en dose-dense arm, respectively. Response rates were 75% and 70%, the progression-free 
survival 6 and 7 months, respectively. 
 
Conclusion 
Dose-dense chemotherapy with a lower cumulative dose, a halved treatment time, but a higher dose-
intensity  may be as effective and safe as dose-escalated chemotherapy. The value of dose-densification 
over standard scheduled chemotherapy regimes yet needs to be determined. 
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Introduction 
In advanced breast cancer anthracycline non-taxane combination regimens as first-
line systemic therapy results in a 30-50% overall response rate, a complete response 
rate of 5-10%, and a median progression-free survival of 4-8 months.1 The 
combination of paclitaxel and doxorubicin showed promising response rates of  83-
95% in clinical phase I and II studies.2,3 The superiority of an anthracycline-taxane 
combination was subsequently confirmed in five randomized phase III studies with 
response rates of 55-68% and a (small) gain in progression-free survival.4-8 Two studies 
showed a significant improvement in overall survival, but at the cost of considerable 
increase in treatment related toxicity, mainly febrile neutropenia, infections and 
cardiac toxicity.  
Epirubicin is a synthetic doxorubicin analogue, with a similar activity but decreased 
toxicity profile, in particular less cardiotoxicity.9 The addition of G-CSF may reduce the 
incidence of febrile neutropenia, but also increases the dose-intensity of cytotoxic 
agents. This can be accomplished by reducing the interval between the 
administrations of “standard doses” of chemotherapy or by increasing the dose with a 
“standard inter-cyclic interval”. These two approaches of dose-intensification have 
also been called “dose-densification” and “dose-escalation”, respectively. However, 
the biological effect and clinical relevance of these approaches may be quite different. 
Dose-densification of chemotherapy may be important to kill chemo sensitive  tumor 
cells, by preventing early regrowth of dormant cells. The major effect of dose-
escalation may be a more effective eradication of resistant tumor cells and the dose 
size may also be the most important factor in reducing the risk of developing resistant 
cells.10,11  
Our group initially investigated both approaches with epirubicin/cyclophosphamide 
combination chemotherapy supported by G-CSF, in the treatment of advanced breast 
cancer. We concluded that dose-densification allowed a higher dose-intensity than 
dose-escalation.12 Based on these results we next determined the maximal dose-
intensity of  the epirubicin/paclitaxel combination supported with G-CSF. In the dose-
dense approach the intercyclic interval of epirubicin 75 mg/m2 and paclitaxel 
135 mg/m2 could be reduced to 10 days. In this 10 days interval it was feasible to 
increase the paclitaxel dose up to 175 mg/m2, enabling a dose intensity of 
52 mg/m2/week for epirubicin and 122 mg/m2/week for paclitaxel, respectively.13 In 
the dose-escalation approach the maximal tolerated doses of a 3-weekly schedule was 
110 mg/m2 for epirubicin and 240 mg/m2 for paclitaxel (unpublished data). The dose-
intensity of this latter schedule is 37 and 80 mg/m2/week, respectively. 
The current randomized phase II study evaluates the efficacy and tolerability of the 
two dose-intensified chemotherapy regimens consisting of epirubicin and paclitaxel, 
supported with G-CSF. The main objective of the study was to test whether a high 
response rate (overall response rate ≥80%) could be achieved. Secondary objectives 
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were to assess the progression-free interval, and evaluate the safety profiles and 
cardiotoxicity. 
Materials and methods 
Patient selection 
The inclusion criteria for women with advanced breast cancer were: measurable and 
histological proven breast cancer; age 18 to 70 years; performance status 0 to 2 
(Eastern Cooperative Oncology Group [ECOG] scale); adequate hematological, hepatic 
and renal function; no prior chemotherapy for metastatic disease; prior adjuvant 
chemotherapy allowed, if interval after last chemotherapy cycle ≥1 year and at entry 
cumulative dose of doxorubicin ≤300 mg/m2 or epirubicin ≤450 mg/m2; normal left 
ventricular ejection fraction (LVEF) assessed using multigated acquisition (MUGA) scan 
and without symptomatic cardiovascular disease. Exclusion criteria were central 
nervous system involvement, history of other malignancy, active infectious disease 
and pre-existing neuropathy. 
Study design 
This open-label multi-centre randomized phase II trial was approved by the 
institutional review boards of the 12 participating hospitals, and the procedures 
followed were in accordance with the Helsinki Declaration 1996 of the World Medical 
Association. Randomization was independently centrally performed, and patients 
were stratified according to participating centre and prior adjuvant anthracycline 
containing chemotherapy (yes/no).  
Pre-study evaluation included history, physical and blood examination, chest x-ray, 
liver ultrasound, skeletal scintigraphy, ECG and cardiac MUGA-scan. Suspected lesions 
were assessed by the best evaluable and reproducible (radiological) technique. Full 
blood count was weekly repeated and routine biochemistry was assessed before each 
cycle. Assessment of LVEF was scheduled at baseline, after treatment cycles three and 
six, before each additional treatment cycle after a cumulative dose of 800 mg/m2 
epirubicin, in case of clinical signs of cardiac failure, if patients went off study, and 
three months after the last chemotherapy cycle.  
In this study the epirubicin (Pfizer Inc., New York, NY) was given as a short intravenous 
infusion, followed by paclitaxel (Taxol®, Bristol-Myers Squibb, New York, NY) as a 
three-hours infusion. A routine premedication regime was adopted to prevent 
hypersensitivity reactions and nausea/vomiting. Concomitant endocrine, 
erythropoietin or prophylactic antibiotic therapy was not allowed. Patients were 
transfused when necessary to maintain a platelet count of ≥15,000/μl and 
hemoglobin level ≥8.0 g/dl. 
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Dose-intensity is defined as the chemotherapy dose per unit time and was expressed 
as mg/m2/week. The cumulative dose is the product of dose per cycle and number of 
cycles of chemotherapy.  
In the dose-escalated arm initially epirubicin 110 mg/m2 and paclitaxel 240 mg/m2  
was given both on day 1, q 21 days, with R-metHuG-CSF (Filgrastim®, Amgen Inc. 
Thousands Oaks, CA) 5 μgr/kg subcutaneously on days 2-14, for six cycles. However 
due to an excess of serious adverse events in four out of the first nine patients, the 
paclitaxel dose was reduced to 200 mg/m2 (see results). The new scheduled 
cumulative doses for epirubicin was 660 mg/m2 and for paclitaxel 1200 mg/m2, and 
the dose-intensity was 37 and 67 mg/m2/week, respectively. 
The dose-dense schedule consisted of epirubicin 75 mg/m2 and paclitaxel  175 mg/m2 
both on day 1 with a 10 days interval, with G-CSF support on days 2–10, for six cycles. 
The scheduled cumulative doses were for epirubicin 450 mg/m2 and paclitaxel 
1050 mg/m2. The scheduled dose-intensity was 52 mg/m2/week and 122 mg/m2/ 
week. (Figure 4.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Study design: dose-escalated and dose-dense epirubicin and paclitaxel. 
 Dose-escalated (upper): epirubicin 110 mg/m2 + paclitaxel 200 mg/m2 Q 21 days, x 6, G-CSF day 
2-14. 
Dose-dense (lower): epirubicin 75 mg/m2 + paclitaxel 175 mg/m2 Q 10 days, x 6, G-CSF day 2-10 
(black: epirubicin; dark gray: paclitaxel; light gray: G-CSF; white: no G-CSF). 
Dose modifications 
Toxicity was assessed after each course according to National Cancer Institute 
Common Toxicity Criteria version 1.0. A 20% dose reduction of epirubicin and 
paclitaxel was recommended in case of nadir thrombocytopenia grade 4, neutropenia 
grade 4 for a period of more than seven days, febrile neutropenia and any non-
hematological toxicity grade ≥3 in the previous cycle. The neutrophil (≥2,000/μl) and 
platelet (≥100,000/μl) counts had to be recovered on the day of scheduled 
chemotherapy. In case of incomplete hematological recovery or persistence of non-
hematological toxicity grade ≥2 (excluding alopecia and anticipatory nausea and 
1
1
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4
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6
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vomiting), treatment was delayed for a maximum period of two weeks. If a longer 
recovery period is needed  the patient went off study.  
Treatment had to be ceased in case of development of clinical cardiac failure or an 
absolute decrease in LVEF either ≥20% (EF absolute units) from baseline to a value 
above 50% or ≥10% to a value below 50%. 
Study end points 
Tumor response evaluation of all known metastases was scheduled after cycle 3 and 6 
by the same pre-study techniques. In addition, extra assessments had to be 
performed if there was clinical suspicion of progression. Standard UICC response 
criteria were applied. 
Statistical considerations 
The main objective of the study was to test whether a high response rate (overall 
response rate ≥80%, with ≥15% complete remission) could be achieved with either 
dose-intensified schedules. A response rate of 60% or lower is also feasible with non-
taxane combination chemotherapy, and considered not interesting for further 
investigation. Using a 90% power and a significance level of 5% in a Simon two-stage 
phase II design for P1-P0=0.20, at least 45 for response evaluable patients in each arm 
were needed. Secondary objectives were to assess the progression-free interval, and 
evaluate the safety profiles and cardiac toxicity of these two approaches separately.  
If a patient continued or restarted with other antitumor therapy without objective 
progressive disease, the patient was censored on this date for progression-free 
survival. 
Results 
Patient characteristics 
In total, 123 patients were entered and randomized in this study.  
After inclusion of the first 18 patients (nine in both arms), an interim safety analysis 
was warranted due to an unexpected high number of dose-limiting toxicities in the 
dose-escalated arm. In contrast with our experiences in the phase I study, where only 
one out of 12 patients developed peripheral neurotoxicity during the first three cycles, 
in this study three out nine patients in the dose-escalated arm developed grade 2-3 
neurotoxicity. These side-effects were debilitating for the patients and prevented the 
patients to undergo scheduled treatment. The dose of paclitaxel in this arm was 
therefore reduced to 200 mg/m², a dose-level that was considered to be effective but 
presumably resulting in less peripheral neurotoxicity. In the dose-escalated arm a new 
cohort of patients was entered at this new dose level up to a total of 50 patients. 
Patients in the dose-dense arm continued to be entered at the original dose level. The 
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randomization procedure was adapted temporarily to a 2:1 design in favor of the 
dose-escalated arm until the disappearance in imbalance of the number of patients.  
So, 114 patients were randomized, excluding the first nine patients in the dose-
escalated arm. Of these, eight patients were shown not to be eligible because of; 
central nervous system tumor involvement (n=3), too high prior adjuvant cumulative 
anthracycline dose (n=2), other antitumor treatment started immediately after 
randomization but prior to scheduled chemotherapy (radiotherapy, n=2) and early 
withdrawal of consent (n=1). All 106 eligible patients were evaluable for the safety 
analysis, 51 in the dose-escalated and 55 patients in the dose-dense arm. The patient 
characteristics in both study arms were well balanced (Table 4.1). Ten and eleven 
patients in each arm presented with primary metastatic disease and about half of the 
patients had undergone prior systemic adjuvant therapy and palliative endocrine 
therapy. In both arms there was a high number of patients with osseous, hepatic 
and/or lymph node metastases. About 40% of the patients had metastases in three or 
more organ systems. 
 
Table 4.1 Patient characteristics.  
Characteristics Dose-escalated 
epirubicin/paclitaxel 
n=51 
Dose-dense 
epirubicin/paclitaxel 
n=55 
 n (%) n (%) 
Median age, years 51 (range  31 - 72) 53 (range 29 - 69) 
ECOG performance status    
 0 23 (45) 30 (55) 
 1 24 (47) 24 (44) 
 2   4   (8)   1   (2) 
Hormone receptor status     
 ER positive 28 (55) 34 (62) 
 PR positive 26 (51) 31 (56) 
Prior adjuvant systemic therapy 20 (40) 26 (47) 
 Endocrine 10 (20) 17 (31) 
 Chemotherapy, anthracyclines 11 (22) 10 (18) 
 Chemotherapy, non-anthracyclines   4   (8)   6 (11) 
Median disease-free interval (months) 28  (range 0-143) 31  (range 0-360) 
Median MBC interval (months)   2  (range 0-76)   3  (range 0-104) 
Primary metastatic 10 (20) 11 (20) 
Prior palliative endocrine therapy 23 (45) 30 (55) 
Metastatic sites     
 Osseous 29 (57) 33 (60) 
 Hepatic 22 (43) 30 (55) 
 Pulmonary 17 (33) 10 (18) 
 Lymph nodes / Soft tissue 27/14 (53/27) 27/8 (49/15) 
 ≥ 3 organ system localizations 21 (41) 22 (40) 
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PR, progesterone receptor; DFS Disease 
Free Survival interval= time interval between primary diagnosis of breast cancer and diagnosis of metastatic 
disease; MBC interval= time interval between diagnosis of metastatic breast cancer and date of 
randomization. 
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Treatment summary 
In both arms, a median number of six cycles was delivered. Forty-two (82%) patients 
completed all six treatment cycles in the dose-escalated arm, with 84% of the cycles 
delivered at ≥90% of scheduled dose-intensity. In the dose-dense arm, forty-three 
(78%) patients completed all six treatment cycles, with 85% of the cycles delivered at 
≥90% scheduled dose-intensity.  
The median delivered cumulative doses and dose-intensities are displayed in Table 
4.2. 
 
Table 4.2 Delivered treatment of epirubicin and paclitaxel. 
 Dose-escalated 
epirubicin / paclitaxel 
Dose-dense 
epirubicin / paclitaxel 
 No of 
patients 
median DI 
mg/m2/wk 
epirubicin 
median DI 
mg/m2/wk  
paclitaxel 
No of 
patients 
median DI 
mg/m2/wk 
epirubicin 
median DI 
mg/m2/wk  
paclitaxel 
Cycle 1   51 37 67   55 53 123 
Cycle 2   49 37 67   55 53 123 
Cycle 3   49 37 67   53 53 123 
Cycle 4   45 37 67   52 48 112 
Cycle 5   44 37 67   49 52 122 
Cycle 6   42 37 67   43 52 122 
Overall 280 36 67 307 51 120 
       
Median Cumulative 
dose 
  
   epirubicin 656 (range 109 - 694) 448 (range 144 - 494) 
   paclitaxel 1194 (range 199 - 1400) 1045 (range 349 - 1165) 
Median cumulative 
total dose epirubicin& 
 
659 (range 109 - 1117) 
 
450 (144 - 902) 
Median treatment 
duration (days) 
 
126 (range 21 - 212) 
 
61 (range 20 - 102) 
& Median total cumulative dose epirubicin; is the cumulative delivered amount of epirubicin during study 
protocol + eventually cumulative dose of adjuvant anthracycline.  
 
Efficacy 
Tumor response was assessable in 48 patients of the dose-escalated arm and 53 
patients of the dose-dense arm (Table 5.3). The best overall response rate was 75% in 
the dose-escalated arm and 70% in the dose-dense arm. All patients ultimately 
developed progressive disease. The median progression-free survival was 6 months 
(95% CI 5.1-6.9) and 7 months (95% CI 5.6-8.4) for the dose-escalated arm and dose-
dense arm, respectively. The median overall survival was 16 months (95% CI 
12.1-20.0) and 14 months (95% CI 9.6-18.4), respectively. 
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Table 4.3 Efficacy of epirubicin and paclitaxel, dose-escalated and dose-dense regimens. 
 
 
Dose-escalated 
epirubicin / paclitaxel 
Dose-dense 
epirubicin / paclitaxel 
No. receiving treatment 51  55  
Assessable for response 48 (%) 53 (%) 
 Overall 36 (75) 37 (70) 
 Complete remission   3   (6)   3   (6) 
 Partial remission 33 (69) 34 (64) 
 Stable disease   9 (19) 14 (26) 
 Progressive disease   3   (6)   2   (4) 
     
Progression 51 (100) 55 (100%) 
Death 48 (94%) 54 (98%) 
     
Median PFS (months, 95%CI)   6 (5.1 – 6.9)   7 (5.6 – 8.4) 
Median OS (months, 95% CI) 16 (12.1 – 20.0) 14   (9.6 – 18.4) 
Total MBC OS (months, 95% CI) 24 (17.8 – 30.2) 26  (15.6 – 36.4) 
PFS, progression-free survival; OS, overall survival; MBC, metastatic breast cancer 
 
Toxicity 
In the dose-escalated arm, twenty-nine (57%) patients had a dose-limiting toxicity at 
the starting dose-level (Table 4.4). Sixteen (31%) patients encountered a grade ≥3 
toxicity, ten (20%) patients had a delayed recovery at the time of the next scheduled 
cycle (partly overlapping reasons for dose-modifications), and four (8%) patients 
showed an asymptomatic but significant decrease of the LVEF. After a first treatment 
modification, additional secondary dose-limiting toxicities occurred in 12 (24%) 
patients. Of the grade ≥3 toxicities, febrile neutropenia, thrombocytopenia and 
neurotoxicity were most frequently seen. Febrile neutropenic episodes all occurred 
during the first cycle (n=6, 12%); one patient died in a septic shock. Grade 3 
neurotoxicity was observed in three (6%) patients after the 3rd , 4th and 5th  cycle, 
respectively. In total eight patients showed an asymptomatic but significant decrease 
of the LVEF. Only one of these eight had received anthracycline-based chemotherapy 
in the adjuvant setting. The onset of cardiotoxicity occurred at a median total 
cumulative dose of epirubicin of 657 mg/m2 (range 556–778). One patient ultimately 
developed symptoms of cardiac failure nine months after stopping study treatment. 
In the dose-dense arm, 27 (49%) patients had a dose-limiting toxicity at the starting 
dose-level. Fourteen (25%) patients with a grade ≥3 toxicity, two (4%) patients with an 
asymptomatic but significant decrease of the LVEF and 11 (20%) patients with a 
delayed recovery precluding the next scheduled cycle. After treatment-modification, 
11 (20%) patients encountered again dose-limiting toxicity which necessitated a 
further treatment-modification. Febrile neutropenia was observed in four (7%) 
patients, of whom one with a fatal outcome after the 6th cycle. One patient with active 
thromboembolic disease developed a cerebrovascular accident and pulmonary 
Thesis_Lalisang_v01.pdf
54⏐Chapter 4 
infection after the first cycle and died after the second cycle. Autopsy revealed 
extensive thromboembolic disease in lungs, liver and kidneys. Peripheral neurotoxicity 
grade ≥3 was observed in five (9%) patients. In total four patients developed an 
asymptomatic but significant decrease of the LVEF. Three of these four had received 
anthracycline combination chemotherapy in the adjuvant setting. In these patients 
the median total cumulative dose of epirubicin, 798 mg/m2 (range 420–850), was 
considerably higher than the subgroup without a fall in LVEF, 450 mg/m2 (range 
144-902). One of these patients ultimately developed symptoms of cardiac failure 
three months later. 
 
Table 4.4 Dose-limiting toxicities initially and later. 
 Dose-escalated 
n=51 
Dose-dense 
n=55 
Toxicities Initial toxicity 
n (%) 
Later toxicity 
n (%) 
Initial toxicity 
n (%) 
Later toxicity 
n (%) 
No. Patients 29 (57) 12 (24) 27 (49) 11 (20) 
         
NCI-CTC ≥grade 3 16 (31)   4   (8) 14 (25)   4   (7) 
 Neutropenic fever   6 (12)   1   (2)   4   (7)   
 Platelets, grade IV   5 (10)   2   (4)   3   (5)   1   (2) 
 Neurotoxicity   3   (6)     5   (9)   2   (4) 
 Infection   2   (4)   1   (2)   1   (2)   
 Gastro-intestinal   1   (2)     4   (7)   1   (2) 
 Skin         1   (2) 
         
Cardiac, serious event   4   (8)   4   (8)   2   (4)   2   (4) 
 Symptomatic         
 Asymptomatic   4   (8)   4   (8)   2   (4)   2   (4) 
         
Delayed recovery 10 (20)   4   (8) 11 (20)   5   (9) 
 Neutrophils   1   (2)     2   (4)   1   (2) 
 Platelets   3   (6)   3   (6)   1   (2)   2   (4) 
 Neurotoxicity   1   (2)   1   (2)   2   (4)   2   (4) 
 Infection   3   (6)     5   (9)   
 Miscellaneous   3   (6)     2   (4)   
Discussion 
In this randomized phase II study two different approaches of dose-intensification of 
an anthracycline/taxane combination were tested for their outcome on response rate, 
progression-free survival and safety profile as first-line chemotherapy in patients with 
advanced breast cancer. Both arms appeared to be very effective with response rates 
of 70% and more. Already after three cycles of chemotherapy the response rates were 
51% for the dose-dense regime (after one month of treatment) and 55% for the dose-
escalated regime (after two months of treatment), respectively. Despite the almost 
halved treatment duration in the dose-dense arm, the progression-free survival 
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seemed to be quite comparable for both treatment arms. Or, in other words, with a 
much shorter treatment period and a lower cumulative chemotherapy dose, patients 
remained longer off-treatment. For the dose-dense regime the treatment-free period 
was five months, whereas for the dose-escalated regime this was only two months. 
Obviously, apart from the benefit for the patient also from an economic viewpoint this 
may be an interesting observation. 
Also, different toxicity frequencies were observed, with a better overall profile for the 
dose-dense regime. In the dose-escalated arm there was a higher incidence of 
hematological toxicity showing more febrile neutropenia (14% vs. 7%), despite the use 
of primary G-CSF prophylaxis, and more grade four thrombocytopenia (14% vs. 7%). A 
higher incidence of mainly asymptomatic cardiac toxicity was also observed in the 
dose-escalated arm (16% vs. 8%), likely associated with the higher cumulative dose of 
epirubicin in this arm, but also the interaction between epirubicin and paclitaxel may 
have played a role. Others have reported that the combination of doxorubicin and 
paclitaxel was associated with the development of heart failure at cumulative 
doxorubicin doses much lower than usual.2 Grade 3 or higher peripheral neurotoxicity 
was observed in 6% and 13% of the patients with the dose-escalated and dose-dense 
regime, respectively. In the CALGB 9840 trial it was shown that weekly paclitaxel was 
indeed associated with significantly more grade 3 neuropathy than the every three-
week therapy.14 However, as weekly paclitaxel was superior to every-three-weeks 
administration in terms of response, median time to progression and overall survival, 
it is now generally appreciated that if there is an indication for paclitaxel in advanced 
breast cancer, it should be used in a weekly dense schedule. The superiority of the 
weekly paclitaxel schedule over a 3-weekly schedule, after four cycles of doxorubicin 
and cyclophosphamide, was also confirmed in the adjuvant setting (ECOG 1199).15 
The introduction of G-CSF permitted the administration of myelosuppressive 
chemotherapy in intervals shorter than the conventional three weeks. However, 
although post-chemotherapy G-CSF reduces neutropenia, G-CSF shortly before 
chemotherapy may increase myelotoxicity. Timmer-Bonte et al. showed that during 
dose-densified chemotherapy daily G-CSF until two days before the next cycle 
compared to G-CSF until five days before the next chemotherapy cycle significantly 
worsened the degree of thrombocytopenia of that next cycle.16 Timely withdrawal of 
G-CSF during dose-densified chemotherapy was advised, to reduce chemotherapy-
related thrombocytopenia without jeopardizing neutrophil recovery. In the present 
study, we administered G-CSF on days 2-10 in the dose-dense arm and on days 2-14 in 
the dose-escalated arm. Nevertheless, the incidence of grade 4 thrombocytopenia 
was not increased but seemed to be even lower in the dose-dense arm when 
compared with the dose-escalated arm. That weekly paclitaxel was also less 
myelosuppressive than 3-weekly paclitaxel was also observed by others.14  
Cytotoxic therapy generally induces tumor regression with repeated cycles. Smaller 
tumors theoretically experience greater log kill (cell kill on a logarithmic scale) when 
chemotherapy is applied, because they are growing more rapidly than larger tumors 
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of the same kinetics. However there is always re-growth between treatment cycles. 
The Norton-Simon hypothesis model suggests that chemotherapy is more effective by 
giving pulses of chemotherapy at a greater dose rate.10,11 By minimizing the regrowth 
of cancer between cycles of treatment, the cumulative cell kill might be enhanced and 
thereby achieving a greater therapeutic effect. The CALGB 9741 trial in node positive 
early breast cancer tested in a 2 x 2 factorial design the role of sequential versus 
concurrent chemotherapy and conventional three-weekly intervals versus “dose 
dense” 2-weekly intervals.17 Although the cumulative doses of doxorubicin, 
cyclophosphamide and paclitaxel were equal in the four arms, the dose intensities 
were quite different. The dose-dense approach resulted in a reduced annual odds for 
disease-recurrence of 26%. Interestingly, the dose-dense arms were also associated 
with less severe neutropenia and neutropenic fever, compared with the conventional 
treatment arms.  
Also in advanced ovarian cancer densification of chemotherapy has been investigated 
by a Japanese study group in a randomized phase 3 study. As first line treatment six 
cycles of either paclitaxel (180 mg/m2; 3-h intravenous infusion) plus carboplatin AUC 
6 mg/ml per min, given on day 1 of a 21-day cycle was compared with dose-dense 
paclitaxel (80 mg/m2; 1-h intravenous infusion) given on days 1, 8, and 15 plus 
carboplatin given on day 1 of a 21-day cycle. In comparison with the conventional 
treatment group the dose-dense treatment group showed a statistically significant 
improved median progression free survival (28.0 vs. 17.2 months) and 3 years overall 
survival (72.1% vs. 65.1%). However the dose dense treatment resulted in more 
frequent hematological toxicity, mainly neutropenia and anemia.18  
When discussing dose density, it is also important to take the issue of combination 
versus sequential administration of cytotoxic drugs into account. With sequential 
schedules, one can aim at a higher dose intensity per drug, but it ignores the concept 
of ‘non-overlapping’ resistance mechanisms which may be better addressed by 
combination chemotherapy. There are several randomized trials that have directly 
compared the combination versus sequence of anthracyclines and taxanes in the 
advanced breast cancer setting.19-21 None of these showed a survival benefit, although 
a higher response rate and longer time to treatment failure with the combination was 
observed in one trial.19 However, the concept of maximizing the dose intensity in the 
sequence using single-agents was not tested. Further of note, the impact of 
densification may be different for a drug like paclitaxel than for an anthracycline.14,22 
At present, in the absence of specific predictive factors to select a subgroup of 
responsive patients, combination chemotherapy may be preferentially reserved for 
patients with rapidly progressing visceral metastatic disease, or in the emergency 
situations in which a rapid response is warranted.23  
In conclusion, we observed that dose-dense and dose-escalated chemotherapy of the 
combination epirubicin and paclitaxel was quite effective. The dose-dense regime 
seemed to be the preferred schedule, because of less side effects. Dose-dense also 
seemed to be more attractive as the treatment was administered over only 60 days 
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compared to almost 130 days in the three-weekly dose-escalated schedule. With a 
comparable time-to-progression this shorter treatment schedule resulted in a 
substantial longer off-treatment period. We feel that in breast cancer the concept of 
dose-density warrants further testing. 
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Summary 
Background 
Despite adjuvant chemotherapy the prognosis of patients with breast cancer and a high number of involved 
axillary lymph nodes is very poor. The aim of the present study was to evaluate the efficacy of high dose 
chemotherapy with autologous bone marrow support in patients with 7 or more involved axillary lymph 
nodes. 
 
Patients and Methods 
Nineteen patients underwent 4 courses of standard adjuvant chemotherapy, followed by high dose 
Busulphan/Cyclophosphamide chemotherapy with autologous bonemarrow support. 
 
Results 
The median age was 41.4 years and the median number of involved lymph nodes was 11. Mucositis WHO 
grade ≥3 was observed in 15 patients and 18 patients suffered febrile neutropenia. Transplant related 
mortality was encountered by 2 patients, due to hepatic veno-occlusive disease and sepsis complicated by 
multi-organ failure, respectively. After a median follow-up period of 1490 days (range 582-2024 days) from 
diagnosis 9 patients have relapsed and the overall event-free survival (EFS) is 42% (95% CI 19-65%). The 
median EFS is 487 days. 
 
Conclusion 
High-dose treatment with BuCy2 in high-risk breast cancer patients is a toxic regimen and does not seem to 
improve the disease-free survival. 
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Introduction 
Adjuvant chemotherapy has demonstrated a modest, but consistent improvement in 
long term disease-free and overall survival in primary breast cancer patients.1 The 
prognosis of patients with primary breast cancer is inversely related to the number of 
involved axillary lymph nodes at surgery. Analysis of treatment outcomes in patients 
with 4-9 positive lymph nodes indicates that 50-60% will relapse by 5 years and 
60-70% will relapse by 10 years.2-4 The outcome of patients with 10 or more positive 
lymph nodes is even worse, at 5-years 55-87% and at 10 years 70-90% have relapsed, 
respectively.2-6 Twenty year follow-up data from the CMF Milan experience suggest 
that even at that time no plateau has been reached.7 
Several studies and retrospective analyses suggest a significant dose-response 
relationship in metastatic and primary breast cancer.8-11 Attempts to further improve 
these results by increasing the dose of chemotherapy have met only limited success, 
mainly due to profound myelosuppression. Autologous bone marrow support (ABMS) 
offers an opportunity to overcome this problem, but whether this will lead to better 
results remains to be determined. 
High dose cyclophosphamide has been shown to induce responses in a variety of 
relapsed or refractory malignancies and has been part of double alkylator therapy 
with autologous bone marrow support in advanced breast cancer.12-14 Alkylating 
agents have shown a steep dose-response relationship in vitro and, when combined, 
act synergistically to produce response rates higher than these produced by single 
agents alone.15,16 
The preparative regimen busulphan and cyclophosphamide (BuCy) has been 
introduced by Santos and colleagues for the treatment of acute non-lymphoblastic 
leukaemia.17 This regimen was altered to decrease the toxicity of cyclophosphamide 
(BuCy2) by Tutschka and coworkers without apparent loss of efficacy.18 Experience 
with BuCy2 showed a relatively low treatment related morbidity, making this bi-
alkylator preparative regimen potentially attractive for the treatment of solid 
tumors.19  
In 1991 we started a phase II study to address the question whether adjuvant 
chemotherapy followed by high dose consolidation with busulphan and 
cyclophosphamide supported by bone marrow transplantation may improve the 
prognosis of patients with primary breast cancer and 7 or more positive axillary lymph 
nodes. 
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Materials and methods 
Patients 
Patients were eligible if they had histologically proven invasive breast cancer, stage II 
or III, and at lumpectomy or mastectomy with axillary node dissection, 7 or more 
positive lymph nodes. After surgery clear surgical margins were required at pathologic 
examination, without signs of locoregional or metastatic disease. No formal extensive 
staging studies except for chest X-ray, bone-scintigraphy and routine laboratory 
examination (complete blood cell counts and biochemistry profile) was done. Patients 
were between 18 and 55 years of age, with a good performance status (ECOG-
ZUBROD <2), adequate bone marrow, cardiopulmonary, neurologic, liver and renal 
function and without prior malignancies. The estrogen-receptor status was assessed 
on the primary tumor by immunochemistry (Diagnostic Products Corporation 
Nederland Ltd, The Netherlands). Informed consent was obtained from all patients. 
Treatment program 
Patients were treated with 3 cycles of standard adjuvant combination chemotherapy. 
Five patients with a lumpectomy underwent concurrent radiotherapy of the involved 
breast. Bone marrow was harvested 4 weeks after the third cycle if routine physical- 
and laboratory-examination appeared normal. The bone marrow was harvested under 
general anesthesia by multiple aspirations from both posterior iliac crests and at least 
0.5 x 108 nucleated cells/kg body weight had to be collected. A buffy coat concentrate 
was cryopreserved using 10% dimethyl sulfoxide, frozen at controlled rate and stored 
in liquid nitrogen. After the harvesting procedure a fourth chemotherapy cycle was 
administered. Between 4 and 6 weeks after this fourth cycle patients were admitted 
for the high dose consolidation chemotherapy. All patients had a double-lumen 
central venous catheter placed and were cared in private rooms with positive-
pressure, high efficiency particle filtration air system. Prophylactic measures consisted 
of a low bacterial and low fungal content diet, oral fungostatics and oral quinolones. 
The high dose chemotherapy program consisted of busulphan 4 mg/kg p.o. in divided 
doses daily days -7 till -4 (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg once 
daily i.v. on days -3 and -2 (total dose 120 mg/kg), followed by bone marrow 
reinfusion on day 0. Throughout the treatment course hemoglobin level was 
maintained above 6 mmol/l and platelet count above 10 x 109/l by transfusion of 
irradiated leukocyte-poor donor red cells and random platelets. During the study 
period the hematopoietic growth factors GM-CSF and later G-CSF became available, 
and were administered, according to local protocols in a dose of 5 μgr/kg body 
weight, from day 1 until leukocyte recovery ≥ 3 x 109/l. Cultures were performed for 
bacterial and fungal infections if a patients temperature was greater than 38.5˚C. 
Febrile neutropenic patients were treated empirically by a standardized antibiotic 
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protocol. Prescription of tamoxifen after hematologic recovery was left to the 
discretion of the physician. 
Follow-up 
After transplantation patients were followed with monthly controls in the first year 
and three monthly controls later, using history, routine physical examination, liver 
enzyme testing and yearly mammography. 
Statistics 
Event-free survival (EFS) was defined as the time from surgery until relapse or death. 
Overall survival (OS) was calculated from surgery until death. The Kaplan-Meier 
product limit method was used to estimate OS and EFS.20 
Results 
Patients 
In the period from November 1991 till October 1995, 19 patients were entered in the 
study. The median age at diagnosis was 41.4 years (range 23-53.8). The median 
number of positive lymph nodes was 11 (range 7-29) out of median number of 17 
(range 7-34) analyzed (Table 5.1). Three patients had 7-9, 13 patients 10-20 and 3 
patients ≥21 involved lymph nodes, respectively. The estrogen-receptor was positive 
in 9 patients. 
Toxicity of high dose chemotherapy 
During the conditioning regimen all patients suffered from nausea and vomiting which 
was alleviated by selective 5-HT3 antagonists. Mucositis WHO grade ≥3 was observed 
in 15 patients, making total parenteral nutrition necessary in 12 patients. After the 
high-dose chemotherapy, the median duration from bone marrow reinfusion to ANC 
>0.5 x 109/l was 12 days (range 11-26). The median duration to unsupported platelets  
≥20 x 109/l was 32 days (range 12-131) days. Eighteen patients suffered from one or 
more episodes of febrile neutropenia. Transplant related mortality was encountered 
by 2 patients both without evidence of relapse (Table 5.1, pat. no. 6 and 19). One 
patient died at day 58 post transplant due to a complicated acalculus cholecystitis 
with septicemia and ultimately a multiple organ failure. The second patient developed 
60 days post transplant a progressive hepatic veno-occlusive disease (VOD), 
complicated by an interstitial pneumonitis, and ultimately died 131 days 
posttransplant. VOD was also observed in another patient 37 days posttransplant, 
with an uneventful recovery. 
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Survival 
After a median follow-up of 1490 days (range 582-2024 days) from diagnosis the 
overall EFS is 42% (95% CI 19-65%)(Figure 5.1). The median EFS is 487 days (192-
1838+) and the median OS was reached after 894 days. There were two treatment 
related deaths. Nine out of 17 remaining patients developed relapsed disease, with a 
median time to relapse of 395 days (range 200-559). Six patients had systemic 
relapses with localizations in the liver, bone, lung, central nervous system and/or 
bone marrow (Table 5.2). One patient relapsed only in the CNS. One patient relapsed 
locoregionally, and was treated with radiotherapy, and she developed liver and bone 
metastasis seven months later. Another patient relapsed at the mastectomy scar and 
was treated with local excision and radiotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Actuarial probability of overall survival (– | –) and event-free survival (– Ì –) for patients with 
primary breast cancer with seven or more involved auxillary lymph nodes, treated with 
consolidation high-dose chemotherapy and autologous bone marrow support. 
Discussion 
We report our results of conventional adjuvant chemotherapy followed by high dose 
BuCy2 chemotherapy with autologous bone marrow support in patients with primary 
breast cancer and at least 7 involved axillary lymph nodes. With a relatively short 
follow-up we encountered a disappointing disease-free survival (42%), which may be 
comparable with the results of conventional adjuvant chemotherapy. 
At Duke University, in a phase II study Peters applied high dose cyclophosphamide, 
cisplatinum and carmustine with autologous stem cell support as consolidation after 
4 cycles of standard dose adjuvant chemotherapy treatment of primary breast cancer 
involving 10 or more axillary nodes.21 At a median follow-up of 2,5 years the DFS was 
72%. At a recent update with a median follow-up of 5-years the DFS was 68%.22 De 
Graaf reported his experience of high dose consolidation with autologous bone 
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marrow support in patients with five or more positive axillary lymph nodes.23 With a 
median follow-up of 36 months the DFS was 84%. Several investigators reported 
recently their experiences with high dose consolidation in this high risk breast cancer 
patient group. With a relatively short median follow-up (7-16 months) the disease free 
survival shows a broad range between 67% and 90%.24-27 Garcia-Conde reported the 
Spanish results of a phase II study of high-dose consolidation in patients with 10 or 
more involved lymph nodes and observed a 2-years DFS of 80% and a 4-years DFS of 
70%, respectively.28  
How can we explain this discrepancy in results? It should be noted that in our trial the 
patients were not screened intensively for metastatic disease at diagnosis, neither at 
time of bone marrow harvest. From a recent report we know when patients with 10 
or more positive nodes are screened more vigorously, with bone marrow biopsies and 
computed tomography scans, up to 27% are found to have detectable disease, that 
would have been missed with our pre-study screening.30 
Although pre-study screening/selection may explain that our results are disappointing 
and comparable with the results of conventional adjuvant chemotherapy treatment in 
this high risk patient group, other explanations should also be considered. Up to now 
our study is the only one which has applied BuCy2 as high dose consolidation in 
adjunct to conventional adjuvant chemotherapy in this high risk patient group. 
Klumpp investigated a standard BuCy preparative regimen in patients with advanced 
chemo sensitive breast cancer.31 Despite a complete response rate of 73%, all patients 
subsequently progressed, with a median time to progression of 164 days. Kalaycioglu 
applied BuCy2 in patients with metastatic breast cancer who had responded to either 
standard chemotherapy or radiotherapy.32 The median time to progression was 7 
months and the 2-years progression free survival was 25%, which is comparable with 
the results of several other reports investigating different preparative regimens. 
Therefore, it is not likely that BuCy2 is an inferior conditioning regimen. 
The relatively high mortality rate (11%) and small sample size (19 patients) do not 
allow firm conclusions. In conclusion our data do not seem to support the use of high 
dose BuCy2 chemotherapy followed by stem cell transplantation as adjuvant therapy 
in high risk primary breast cancer. 
Presently two large cooperative group (ECOG, CALGB) randomized trials are 
evaluating the role of high dose chemotherapy in patients with 10 or more positive 
nodes are ongoing. In January 1994 a randomized study has been started in The 
Netherlands to investigate the value of HDCT in patients with four or more involved 
axillary lymph nodes. The results of these randomized studies should determine if 
high dose chemotherapy will have a definitive place. 
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Letter to the editor 
Dear editor, 
 
In the late nineties of the previous century high dose chemotherapy followed by 
autologous stem cell transplantation for locally advanced breast cancer attracted a lot 
of interest. Several uncontrolled trials suggested a benefit for these patients. 
Between 1991 and 1995, we performed a phase II trial in 19 breast cancer patients 
with at least 7 or more involved axillary lymph nodes.1 Pretransplant conditioning 
consisted of high-dose busulphan and cyclophosphamide followed by peripheral 
blood stem cell support.  
Now, with a median follow up of more than 16 years (range 14.3-18.2) after diagnosis, 
we present the updated results. Two patients encountered early treatment related 
mortality. Twelve patients relapsed and ultimately died of breast cancer. One patient 
developed a new contra lateral breast cancer almost 15 years after primary diagnosis 
and underwent a mastectomy and received again adjuvant systemic therapy. Of 
importance, even after 9 years three patients developed a relapse and died from the 
original disease. At this moment the overall event free survival (EFS) is 21% with an 
overall survival (OS) of 26% (see Figure 5A.1). The five patients with continued disease 
control all had estrogen hormone receptor negative disease. At that time, 
progesterone receptor and HER2 status was not determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5A.1 Event-free and overall survival in months  
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The West German study group compared, in 403 patients with breast cancer and at 
least 9 involved lymph nodes, dose-dense conventional chemotherapy with rapidly 
cycled tandem high-dose chemotherapy plus autologous stem cell support in a 
prospective randomized trial.2 With a median follow-up of 61.7 months, the 5-year 
EFS (62% versus 41%, hazard ratio =0.60, P=0.004) as well as OS (76% versus 61%, 
hazard ratio =0.58, P=0.007) were significantly better in the high dose chemotherapy 
arm. Recently they evaluated the prognostic and predictive impact of protein 
expression of various molecular markers in the study population. Interaction analysis 
showed that regarding predictive effects, triple negative (ER/PR/HER2 negative) and 
grade 3 tumors derived most benefit from high dose chemotherapy. They concluded 
that tandem high dose chemotherapy improved both EFS and OS in locally advanced 
breast cancer and that this therapy effect may be partly attributable to superior 
efficacy in the subgroup of grade 3 and/or triple-negative tumors.3 
To this end, fifteen study groups have reported their results of randomized controlled 
trials comparing high dose chemotherapy with stem cell autografting versus 
conventional chemotherapy for women with locally advanced breast cancer. There 
was a considerable variation among the chemotherapy regimens used in the different 
trials, but no trial included taxanes as part of the systemic adjuvant treatment. No 
individual trial, except the West Germany study, could report an overall survival 
benefit for high dose chemotherapy. 
Farquhar et al performed a meta analysis on 13 of these trials.4 Six trials had mature 
data on EFS and OS, and the remaining trials with shorter follow-up reporting 
estimated survival rates. At three and four years of follow-up there was a statistically 
significant benefit in EFS for women in the high-dose arm (RR 1.19 and 1.24), which 
bordered statistical significance at five years (RR 1.06), but which was absent at 
6 years of follow-up. It was not possible to demonstrate an OS benefit at any stage of 
follow up. In fact, there was evidence of harm, with a greater number of treatment 
related deaths (RR 8.58) and adverse events in the high dose arm. Even with recent 
developments in supportive care and improvements in the treatment related 
mortality of high dose chemotherapy, it is not expected that this will result in a 
sustained benefit in disease-free survival (DFS) over conventional adjuvant systemic 
therapy, at least not for unselected breast cancer patients. 
De Laurentiis conducted a meta-analysis of randomized trials that evaluated the 
efficacy of incorporating taxanes into anthracycline-based regimens for early breast 
cancer.5 Thirteen studies were included in the meta-analysis (n=22,903 patients). The 
pooled hazard ratio estimate was 0.83 (95% CI, 0.79 to 0.87; P<0.00001) for DFS and 
0.85 (95% CI, 0.79 to 0.91; P<0.00001) for OS. He concluded that the addition of a 
taxane to an anthracycline-based regimen improved the DFS and OS of high-risk early 
breast cancer patients. The DFS benefit was independent of estrogen receptor 
expression, degree of nodal involvement, type of taxane, age/menopausal status of 
patient, and administration schedule. 
Thesis_Lalisang_v01.pdf
 Addendum⏐75 
The reduction in cause-specific mortality from breast cancer that has been 
demonstrated in almost every Western nation over the last decade is felt to be due, at 
least in part, to the widespread application of adjuvant systemic therapy. Recent 
developments incorporating trastuzumab therapy in patients with tumors HER2 gene 
amplification and aromatase inhibitors in patients with a positive hormone receptor 
has also improved the outcome in early breast cancer considerably, in addition to the 
impact of taxanes.  
We conclude that if there is any potential benefit of high dose chemotherapy with 
autografting over conventional chemotherapy, this will be small and may only be  
present in the triple negative subset of patients. However, for most of the patients 
combinations including both anthracyclines and taxanes is more easier and safer 
therapeutic approach. Further studies aimed at optimizing anthracyclines and taxanes 
in combination, and integrating biologic agents based on biological/molecular tumor 
factors, seems to be the way forward. 
 
Roy I. Lalisang 
Vivianne C.G. Tjan-Heijnen 
Harry C. Schouten 
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Abstract 
Fifteen patients with chemo-sensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) 
allogeneic stem cell transplantation (allo-SCT) between 1999 and 2006. Purpose of this single centre study 
was to evaluate the feasibility, safety and efficacy of this therapeutic approach. 
The pre-transplant conditioning regimen consisted of fludarabine (25 mg/m2 at days -5 to-1) and 
cyclophosphamide (60 mg/kg at days –2, -1). Stem cells were from HLA-matched sibling donors. 
The treatment related mortality was 2/15 (13%). Median progression-free survival (PFS) and overall survival 
(OS) was 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and 
the 1-year and 2-year OS was 40% and 20% respectively. No objective tumor responses were observed, but 
the relatively long PFS does suggest a graft versus tumor effect.  
Although RIST using this cyclophosphamide/fludarabine regimen is feasible, the efficacy in this set of 
patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms 
of anti-tumor effects in breast cancer. 
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Introduction 
Conventional allogeneic stem cell transplantation (allo-SCT) represents an accepted 
curative option for a variety of hematologic malignancies and other disorders such as 
severe aplastic anemia, hemoglobinopathies and immunodeficiency disorders.1,2 
Nevertheless, these transplants are complicated by a relatively high treatment related 
mortality (TRM) caused by toxicity of the myeloablative conditioning, graft-versus-
host disease (GVHD) and infections.3 Therefore this type of transplantation is 
generally limited to patients younger than 40-50 years of age with good health status. 
Since the median age for many solid tumors and hematological malignancies is over 
50 years, only a minority of patients may benefit from conventional allo-SCT. 
In recent years non-myeloablative or reduced intensity (RIST) conditioning regimens 
have been developed mostly consisting of purine analogue (Fludarabine) in 
combination with cytotoxic, immunosuppressive drugs or low-dose total body 
irradiation (TBI).4 Nowadays, this type of pre-transplantation conditioning is used for 
both solid tumors and hematological malignancies, especially, in patients with 
advanced age (>55 years), poor disease status, previous intensive treatment, and 
refractory solid malignancies. Data from recent studies show a decreased treatment 
related mortality (TRM) and/or less acute GVHD after RIST if compared with 
conventional myeloablative allo-SCT.5-8 
In this manuscript we describe the largest single centre experience with RIST allo -SCT 
in metastatic breast cancer (MBC). Fifteen subsequent patients with MBC underwent 
a RIST allo-SCT with a conditioning regimen consisting of fludarabine and 
cyclophosphamide with proven engraftment, also in solid tumors.9 The presented 
data from one single center are supporting recently published promising data of the 
European Group for Blood and Marrow Transplant registry (EBMT) and MD Anderson 
Cancer Centre10 and a recent review reporting relatively high response rates and 
supporting the role of allo-SCT for solid tumors.11 
Patients and methods 
Patients eligibility 
To be included in this phase II study patients had to have a chemo-sensitive MBC, a 
(biological) age less than 65 years, minimal tumor load, HLA-identical sibling donor, 
measurable or evaluable disease, an expected life expectancy >3 months and 
informed consent given. Exclusion criteria were pregnancy or lactating, active 
infections, other serious underlying condition, and concurrent treatment with other 
experimental agents. 
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Treatment schedule 
Stem cells were obtained from HLA-identical related donors by leukapheresis after 
stimulation with Filgrastim (10 μg/kg). The conditioning regimen consisted of 
fludarabine 25 mg/m2 at days –5, -4, -3, -2 and –1 and cyclophosphamide 60 mg/kg at 
days –2 and –1. Subsequently, all patients were transplanted with unmanipulated 
peripheral blood stem cells (PBSC). We aimed for at least 4x106/kg CD34 positive cells. 
Prophylaxis for GVHD consisted of standard cyclosporine-A and standard 
methotrexate.12 
After relapse, progression or in the case of incomplete chimerism at 30 days after 
transplantation (<80% donor cells) cyclosporine-A was discontinued earlier. In case of 
no improvement after one month patients were treated with donor lymphocytes 
infusions (DLI) 1 x 107 CD3+/kg followed by, if no improvement, monthly increasing 
numbers of T lymphocytes (5 x 107 CD3+/kg and 10 x 107 CD3+/kg). 
Evaluations and definitions 
Diagnosis and clinical grading of acute and chronic GVHD were performed according 
to established criteria.13,14 Donor-host chimerism levels for sex-mismatched SCT were 
analyzed by fluorescent in situ hybridization (FISH) with probes specific for the X and 
Y chromosome. For recipients of sex-matched SCT, chimerism was assessed using 
polymerase chain reaction-based amplification of short tandem repeat polymorphism 
(STRP) sequences unique to donors and hosts. Treatment related mortality was 
defined as death if there was at time of death no evidence of disease relapse or 
progression. 
Supportive care 
Infection prophylaxis, supportive care and follow-up were carried out according to 
standard local policy. 
Objectives 
The primary objective of this prospective study was whether RIST allo-SCT could 
produce a graft versus tumor (GVT) effect in metastatic breast cancer, evidenced by 
tumor response after post-transplant immune manipulation, and improved 
progression-free survival (PFS) and overall survival (OS). Other study end points were 
treatment related mortality and GVHD. Data were included till July 2008. PFS and OS 
were compiled using the Kaplan-Meier analysis. 
The number of patients to be included in this phase II study was 20, however, due to 
slow accrual and changing oncology practices the study was closed after the inclusion 
of 15 patients. 
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Results 
Between March 1999 and October 2006, 15 patients with MBC, fulfilling the entry 
criteria, were treated with a RIST conditioning regimen followed by an allo-SCT using 
HLA identical sibling donors. The basic characteristics of the patients are presented in 
Table 6.1. The median age was 49.5 years (range 39.7-60.8 years). All patients had a 
WHO performance status 0-1 at admission for transplantation. The median time 
interval from the initial diagnosis of breast cancer till transplant was 6 years (range 0.6 
-20.3 years). All patients were extensively pre-treated and all had at least undergone 
one palliative chemotherapy regimen for metastatic disease. 
 
Table 6.1 Patient characteristics. 
UPN Age at BMT Interval Diagnosis BMT (yrs) PFS (days) Survival (days) 
  73 51,0   7,4 138   138 
  75 43,7   6,0   71   413 
  76 50,4   7,0   74   129 
  82 45,9   5,9 105   303 
  84 60,8   0,6 312 1370 
101 49,7   4,1 509 1376 
119 55,7 20,3 233   586 
126 47,0   2,5   90   228 
138 59,2 12,5   43   123 
142 59,8   5,3 461   478 
145 47,4   9,0 218   263 
191 48,9   3,1 144   144 
196 43,8   8,5 350   401 
208 39,7   3,6 382   704 
226 49,5 13,8 100   122 
 
 
The median number of CD34
+
 cells harvested from HLA-identical sibling donors by 
leukapheresis was 4.4 x 106 CD34
+
 cells/kg of the recipient (range 1.5-15.5). 
All patients ultimately died: two out of 15 patients (13% TRM) died without proven 
tumor progression, 138 and 144 days post-transplant, respectively. These two 
patients died of infectious complications. All other died of disease progression. The 
median PFS and OS was 144 days (43-509 days) and 303 days (122-1376 days), 
respectively (see Figures 6.1 and 6.2). The 1-year PFS was 20%, and the 1-, 2- and 
3-year OS was 40%, 20% and 13%, respectively.  
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Figure 6.1  Progression-free survival in 15 patients with metastatic breast cancer after reduced intensity 
transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Overall survival in 15 patients with metastatic breast cancer after reduced intensity 
transplantation. 
 
The occurrence of acute GvHD was very low, grade 1-2 and 3-4 was observed in one 
patient each (upn 142 and 145). Also limited and extensive chronic GvHD occurred 
infrequently, each in one patient (upn 142 and 145). These two patients had a PFS and 
OS close to the median. 
Ten of the 15 (67%) patients received DLI: three patients once, two patients twice, 
three patients three times, and two patients four times. No objective tumor responses 
were observed. In one patient a tumor marker decline was observed. After initial 
progression she responded temporarily after DLI infusions, as measured with CA 15-3 
(see Figure 6.3). 
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Figure 6.3 One patient (upn 101) with metastatic breast cancer, progressing after RIST, with a temporary 
tumor marker response to increasing doses of DLI. 
 
Discussion 
Here, we describe the results of a phase II study applying RIST allo-transplantation in 
15 MBC patients after a fludarabine and cyclophoshamide conditioning regimen. We 
conclude from this study that the TRM was relatively low (13%), the GvHD limited, and 
no objective tumor response was observed other than a temporary CA15-3 response 
after DLI. 
To interpret our data more carefully, comparative data should be available, which is 
not the case in this phase II study. However, the absence of major responses and only 
one temporary tumor marker CA 15-3 decline after DLI suggests that the anti-tumor 
effect in this group of patients with MBC is limited. Also patients with acute or chronic 
GVHD did not appear to do better. 
Previous publications, with generally smaller numbers than this study, were mainly 
single center studies with more or less promising results. Carella et al.15 reported an 
overall response rate of 24%, after a tandem approach, consisting of high-dose 
chemotherapy with autologous SCT to achieve maximum tumor reduction before 
proceeding to allo-SCT. Bishop et al.16 observed that objective tumor regressions in 
33% of the patients were attributable to allogeneic lymphocyte infusions. Ueno et al.17 
Thesis_Lalisang_v01.pdf
84⏐Chapter 6 
treated 10 patients with MBC observing 2 CR’s and one minimal response. Bregni et 
al.18 observed a partial remission in 2 (33%) patients.  
Recently an overview of international collaboration was published.10,11 In these 
studies response rates attributable to a GVT effect were 16–37%, concluding that a 
GVT effect exists in MBC. Ueno reported that in myeloablative conditioning regimen, 
the development of acute GVHD was associated with an increased risk of treatment 
failure (progression, relapse or death). However, in women treated with RIST, there 
was a decreased risk of treatment failure associated with the development of acute 
GVHD. In his report the cumulative incidence of grade II-IV acute GVHD at 100 days 
was 44% after myeloablative conditioning and 34% after RIST. The cumulative 
incidence of chronic GVHD at 1 year was much higher in the myeloablative group 
(36%) than in the RIST group (8%).10  
In MBC the median PFS and OS with second-line and higher lines of chemotherapy is 
in the range of 3-4 months and 8-12 months, respectively.18 
In our heavily pretreated group the median PFS was almost 5 months, which despite 
the absence of an objective tumor response, does suggest a GVT effect.  
We conclude that routine application of non-myeloablative transplantation for MBC 
may lead to small benefit in PFS.  
The anti-tumor effect after allogeneic transplantation relies more or less on a T cell 
effect. We feel that this effect is limited. We cannot exclude that a different approach 
exploiting a NK-cell effect, like in haplo-identical transplants, would result in a better 
outcome.19,20 
Future clinical trials should be performed to improve the knowledge of mechanisms of 
anti-tumor effects in breast cancer.10,11 
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Summary, conclusions and future perspectives 
Breast cancer is the most common female cancer type in the western world, the most 
common cause of cancer death in women, and the main cause of death in women 
aged between45 to 55 years. In the early and locally advanced disease setting cure 
may be achieved by adding systemic therapy to locoregional therapy. However, as 
soon as disease has spread beyond nearby localized lymph nodes, the disease is 
considered not curable anymore. Although the majority of patients with metastatic 
breast cancer will experience an initial response or stabilization of the disease on 
various combination chemotherapy regimens, many relapses occur within one year 
and the median overall survival after start of treatment is limited to on average two to 
three years.  
 
The aim of dose intensification of chemotherapy is to increase the dose size and/or 
dose frequency beyond the limit of normal bone marrow tissue tolerance, with the 
intention to maximize antitumor efficacy. Dose intensity, dose size and cumulative 
dose may each have important but different effects on outcome. According to the 
analysis of Goldie and Coldman the main effect of a high dose intensity is a more rapid 
and effective eradication of sensitive tumor cells, with the dose size the most 
important factor in reducing the chance of developing resistant cells.1 Norton showed 
that a Gompertzian growth model precisely fitted in the growth curves of breast 
cancer.2 In this model, when a patient with advanced breast cancer is treated and the 
tumor mass is large, its growth fraction is low and the fraction of cells killed is low. 
Shortening of intervals ("dose-dense chemotherapy") may be important to overcome 
this cytokinetic resistance of tumors, by killing chemosensitive cells and recruiting 
regrowth of dormant cells, which will be killed by the subsequent cycle.  
Chemotherapy intensification has met only limited success, mainly due to profound 
myelosuppression. Hematopoietic growth factors, and particularly Granulocyte Colony 
Stimulating Factor (G-CSF), offer an opportunity to overcome this problem.3 The 
addition of G-CSF may not only reduce the incidence of febrile neutropenia, but also 
supports an increase in dose-intensity of cytotoxic agents by allowing a higher dose of 
chemotherapy per course (dose-escalation) or by allowing a shortening of interval 
between courses (dose-densification). Both approaches may lead to a higher dose-
intensity, but their biological effect and thereby clinical relevance may be quite 
different as has been pointed out by Henderson in his review on the dose-intensity 
phenomenon in breast cancer.4 The relative merits of these two approaches have not 
been studied systematically.  
 
In advanced breast cancer anthracycline non-taxane combination regimens as first-
line systemic therapy result in a 30% to 50% overall response rate, with a complete 
response rate of 5% to 10% and a median progression-free survival of four to eight 
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months. Epirubicin is a synthetic doxorubicin analogue, with a similar activity but 
decreased toxicity profile, in particular less cardiotoxicity.5 
 
In Chapter 2 the results of a comparative study of dose escalation versus interval 
reduction to obtain the maximal dose intensity of epirubicin and cyclophosphamide 
with G-CSF in advanced breast cancer is described. The second aim was to assess the 
safety profiles of these intensified schedules. 
In this multicentre study, 49 advanced breast cancer patients were treated with daily 
G-CSF injections and either increasing doses of epirubicin and cyclophosphamide with 
fixed intervals (arm 1) or progressively shorter intervals with fixed doses of epirubicin 
and cyclophosphamide (arm 2). A cohort of at least 6 patients was studied at each 
interval/dose. A more intensified interval/dose was given if less than 50% of patients 
encountered a dose intensity limiting criterium in the first 3 courses. 
In arm 1, epirubicin/cyclophosphamide 140/800 mg/m2 q 21 days was too toxic. 
Subsequently epirubicin/cyclophosphamide 120/700 mg/m2 was tested with 2 out of 
10 patients encountering a dose limiting toxicity. All initial dose limiting toxicities 
consisted of febrile neutropenia. In arm 2 epirubicin/cyclophosphamide 
75/500 mg/m2 could be administered safely with 14 and 12 days intervals. In the 10 
days interval 8 out of 12 patients completed the first 3 cycles without a dose limiting 
toxicity. In the 8 days interval 7 out of 8 patients encountered a dose limiting toxicity. 
Incomplete neutrophil recovery, and to a lesser extent stomatitis, was dose limiting. A 
clinically asymptomatic cardiotoxicity was observed in 21% of patients treated with 
the shorter intervals, that appeared however reversible with longer follow-up. 
In combination with G-CSF, epirubicin/cyclophosphamide 120/700 mg/m2 q 21 days 
was feasible, with a projected dose intensity of 40 mg/m2/week and 233 mg/m2/ 
week, respectively. Epirubicin/cyclophosphamide 75/500 mg/m2 could be 
administered safely every 10 days, allowing a superior projected dose intensity of 
52.5 mg/m2/week and 350 mg/m2/week, respectively.  
In conclusion, with the addition of G-CSF shortening of intervals with standard doses 
of chemotherapy seems to be a more effective method of dose intensification, when 
compared to increasing doses of chemotherapy at fixed intervals. 
 
Apart from anthracyclines, taxanes belong to the most active single agents in 
advanced breast cancer. Paclitaxel is highly active and lacks cross-resistance with 
other drugs commonly used in breast cancer treatment.6,7 The combination of 
paclitaxel and doxorubicin showed promising response rates of 83% to 95% in clinical 
phase I and II studies. The superiority of an anthracycline-taxane combination was 
subsequently confirmed in five randomized phase III studies with response rates of 
55% to 68% and a (small) gain in progression-free survival.8-12 Two studies showed a 
significant improvement in overall survival, but at the cost of considerable increase in 
treatment related toxicity, mainly febrile neutropenia, infections and cardiac toxicity.  
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Chapter 3 describes a study in metastatic breast cancer with the aim of increasing the 
dose-intensity of the epirubicin and paclitaxel combination by shortening cycle time. 
The objective was to define the shortest feasible chemotherapy interval and to assess 
the safety profile of this dose dense approach, supported by G-CSF.  
We treated thirty-six patients with advanced breast cancer in a multicenter phase I/II 
study. The treatment regimen consisted of epirubicin 75 mg/m2 followed by paclitaxel 
135 mg/m2 (3-hours) in combination with G-CSF (5 μg/kg). At least 6 patients were 
treated in each cohort and were evaluated over the first 3 cycles. 
Starting at an interval of 14 days, in subsequent cohorts of patients the interval could 
be shortened to 10 days. The 8-days interval was not feasible mainly due to 
incomplete neutrophil recovery at the day of the next scheduled cycle. In the cohort 
of 10 days interval it was even feasible to increase the paclitaxel dose to 175 mg/m2. 
The treatment related toxicity was relatively mild. Nine out 36 patients developed a 
dose limiting toxicities in the first 3 cycles. Initial dose limiting toxicities were 
incomplete hematological recovery at the day of scheduled cycle in five, febrile 
neutropenia in one and non-hematological in the remaining three patients, 
respectively. No cumulative myelosuppression was observed over at least 3 
consecutive cycles. In our study already after three short interval cycles a response 
rate of 53% was observed.  
In conclusion, with the addition of G-CSF, shortening of intervals of chemotherapy 
seems to be a feasible method of dose intensification, allowing a dose intensity of 52 
mg/m2/week for epirubicin in combination with 122 mg/m2/week of paclitaxel, 
respectively.  
The efficacy and clinical relevance of this approach, have to be investigated in a phase 
II study. 
 
The two approaches of dose-intensification, either escalation or densification, 
regarding the combination of epirubicin and paclitaxel, have been investigated in 
Chapter 4. This multicentre randomised phase II study investigated epirubicin 
110 mg/m2 combined with paclitaxel 200 mg/m2 every 21 days and epirubicine 
75 mg/m2 combined with paclitaxel 175 mg/m2 every 10 days, both supported with G-
CSF. Patients with advanced breast cancer and without prior palliative chemotherapy 
were scheduled for 6 cycles. 
One hundred and six patients were evaluable for toxicity and 101 patients for 
response. Grade ≥3 toxicities occurred in 39% of patients in the dose-escalated arm 
and in 29% of patients in the dose-dense arm, consisting mainly of febrile 
neutropenia, thrombocytopenia, neurotoxicity. A higher incidence of mainly 
asymptomatic cardiac toxicity was also observed in the dose-escalated arm (16% vs 
8%), likely associated with the higher cumulative dose of epirubicin in this arm, but 
also the interaction between epirubicin and paclitaxel may have played a role. The 
median delivered cumulative doses for epirubicin/paclitaxel were 656/1194 mg/m2 
and 448/1045 mg/m2, treatment durations were 126 and 61 days, and delivered dose 
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intensities for epirubicin/paclitaxel were 36/67 and 51/120 mg/m2/week for the dose-
escalated en dose-dense arm, respectively. Both arms appeared to be very effective 
with response rates of 70% and more. Already after three cycles of  chemotherapy the 
response rates were 51% for the dose-dense regime (after 1 month of treatment) and 
55% for the dose-escalated regime (after 2 months of treatment), respectively. 
Despite the almost halved treatment duration in the dose-dense arm and a lower 
cumulative chemotherapy dose, the progression-free survival (6 and 7 months, 
respectively) seemed to be quite comparable for both treatment arms. For the dose-
dense regime the treatment-free period was five months, whereas for the dose-
escalated regime this was only two months.  
The dose-dense regime seemed to be the preferred schedule, because of less side 
effects and with a comparable time-to-progression this shorter treatment schedule 
resulted in a substantial longer off-treatment period. We feel that in breast cancer the 
concept of dose-density warrants further testing.  
 
In early stage breast cancer, adjuvant systemic therapy demonstrated a modest, but 
consistent improvement in long term disease-free and overall survival. Attempts to 
further increasing the dose of chemotherapy are limited mainly due to profound 
myelosuppression, even with the support of hematopoietic growth factors. 
Autologous stem cell transplantation offers an opportunity to overcome this problem, 
but whether this will lead to better results in terms of  disease free en overall survival 
was at the time unclear.  
 
In Chapter 5 we tested the concept of high dose chemotherapy with autologous bone 
marrow support as consolidation after standard-dose adjuvant therapy in primary 
breast cancer patients with 7 or more involved axillary lymph nodes.  
In the period from November 1991 till October 1995, 19 patients with at least 7 or 
more involved axillary lymph nodes underwent 4 cycles of standard adjuvant 
chemotherapy, followed by high dose chemotherapy (busulfan and cyclo-
phosphamide) and autologous bone marrow support. The median age was 41 years, 
the median number of involved lymph nodes was 11 (range 7–29) and the tumors 
were estrogen-receptor positive in 9 patients.  
With a relatively short median follow-up of 45 months we encountered two patients 
with a treatment related mortality, and nine patients with relapsed disease. The 
median event-free and overall survival was 16 months and 27 months, respectively. A 
recent update after a follow-up of more than 16 years, showed that 12 of the 19 
patients have relapsed and ultimately died, resulting in a overall event-free and 
overall survival of 26%.  
High-dose treatment with autologous bone marrow support in high-risk locally 
advanced breast cancer patients is a toxic regime and does not seem to improve 
survival, at least not for unselected breast cancer patients. 
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Autologous bone marrow transplantation as a method to support high-dose 
chemotherapy is one possible way to go. Allogeneic stem cell transplantation may be 
an alternative approach.  
Conventional allogeneic stem cell transplantation is an accepted curative option for a 
variety of hematologic malignancies and other disorders. However, complicated by a 
relatively high treatment related mortality caused by toxicity of the myeloablative 
conditioning, graft-versus-host disease and infections, the indication is generally 
limited to patients younger than 40-50 years of age with good health status. Since the 
median age for many solid tumors and hematological malignancies is over 50 years, 
only a minority of patients may benefit from conventional allogeneic stem cell 
transplantation. In recent years non-myeloablative or ‘reduced intensity conditioning’ 
regimens have been developed with allogeneic stem cell transplantation. The goal of 
this approach is to obtain tumor cell kill from T-cell effects, so called graft-versus-
tumor-effect, and not primarily from delivered chemotherapy effects. This type of 
pre-transplantation conditioning may be interesting for both solid tumors and 
hematological malignancies. An overview of international collaboration reported 
response rates attributable to a graft-versus-tumor effect of 16% to 37%, concluding 
that a graft-versus-tumor-effect exists, also in metastatic breast cancer.13,14 
 
Chapter 6 provides the results of a phase II study of HLA-matched allogeneic stem cell 
transplantation after reduced intensity conditioning with fludarabine/cyclophos-
phamide in 15 patients with metastatic breast cancer. Purpose of this single centre 
study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. 
The pre-transplant conditioning regimen consisted of fludarabine (25mg/m2 at days -5 
to-1) and cyclophosphamide (60 mg/kg at days –2, -1). Stem cells were from HLA-
matched sibling donors. The treatment related mortality was 2 out of 15 (13%). 
Median progression-free survival and overall survival was 144 days (43-509 days) and 
303 days (122-1376 days), respectively. The one year progression free survival was 
20%, and the one year and two years overall survival was 40% and 20%, respectively. 
No objective tumor responses were observed.  
Although ‘reduced intensity conditioning’ allogeneic stem cell transplantation is 
feasible, the efficacy in this set of patients was limited. Future clinical trials should be 
performed to improve the knowledge of mechanisms of anti-tumor effects in breast 
cancer. 
In summary 
We have shown that in the advanced breast cancer setting dose-densification of 
taxane and nontaxane regimens compared to dose-escalation results in a higher 
chemotherapy dose-intensity and a lower cumulative dose. Moreover, there is a 
suggestion of increased efficacy and improved toxicity profile for the dose-dense 
regimens. Others have also shown that dose-dense chemotherapy was superior to 
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standard-dose chemotherapy.15 Due to the limited data, the concept of dose-
densification with only modest increase in dose-intensity is, however, still debated 
and not widespread used. The only exception is the administration of paclitaxel. Both 
in the adjuvant and metastatic setting it was shown that paclitaxel given weekly was 
superior to a 3-weekly regimen in terms of response rate  and survival.16,17 
Regarding the value of high dose chemotherapy with autologous bone marrow 
support as consolidation after standard-dose adjuvant therapy in primary breast 
cancer, we observed a long term survival rate probably not superior to the ones 
reported in literature obtained by conventional chemotherapy. In a meta analysis on 
13 of these trials there was no overall survival benefit compared with standard 
chemotherapy.18 In fact, there was evidence of harm, with a greater number of 
treatment related deaths.  
As an alternative for high dose chemotherapy with autologous bone marrow support, 
we tested the strategy of ‘reduced intensity conditioning’ with allogeneic stem cell 
transplantation. Although this strategy was feasible, the efficacy was limited. 
Current standards 
A meta-analysis of survival data from 128 randomized trials concluded that the gains 
in absolute survival from anthracyclines, taxanes, novel nontaxanes such as 
capecitabine and gemcitabine, either as monotherapy or combined therapy, ranged 
from 4.2 to 12.5 months for a patient with an anticipated survival of one year treated 
with the reference standard alone.19  
Recent trials indicate that combinations including both anthracyclines and taxanes in 
the adjuvant setting may be superior to the older regimens.20  
Future perspectives 
Major developments in the field of systemic therapy for breast cancer have been 
made during the last decade due to developments in the field of molecular oncology. 
For instance, the introduction of third generation aromatase inhibitors with increasing 
insights in endocrine pathways and working mechanisms have changed the endocrine 
treatment field dramatically. But, even more important was the discovery of the 
receptors of the HER-family, with the HER2 at present being the most exciting target 
in breast cancer. Approximately 20 percent of breast cancers have amplified levels of 
the proto-oncogene HER2. Amplified/overexpressed HER2 predicts for response to 
therapies that target HER2, such as the humanized monoclonal antibody trastuzumab 
and the small molecule tyrosine kinase inhibitor lapatinib.21 Other developments in 
the field of targeted therapies include the Vascular Endothelial Growth Factor (VEGF)-
related therapy by antibodies or tyrosine kinase inhibitors and the Poly ADP Ribose 
Polymerase (PARP) inhibitors, specifically in the triple negative patient groups. 
The identification of these molecular pathways may in due time also improve patient 
selection for classical chemotherapeutic agents such as anthracyclines and taxanes. If 
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indeed patients with a chemosensitive tumor can be identified by biological 
parameters, one may hypothesize that even small chemotherapy administration 
modifications may have a significant impact on outcome. So, the increasing insights in 
molecular pathways may facilitate the study on chemotherapy dose-densification in 
selected patients.  
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Samenvatting, conclusies en toekomstige ontwikkelingen 
In de westerse wereld is het mammacarcinoom de meest frequent voorkomende 
maligniteit bij vrouwen. Het is tevens de meest frequent voorkomende doodsoorzaak 
aan kanker en daarbij de meest frequente doodsoorzaak bij vrouwen tussen het 45ste 
en 55ste levensjaar. Bij de vroege stadia en bij het lokaal gevorderd stadium 
borstkanker bestaat de in opzet curatieve behandeling uit locoregionale therapie 
(chirurgie, al dan niet in combinatie met radiotherapie) en eventueel adjuvante 
systemische therapie. In die situaties, waarbij de ziekte zich verder heeft uitgebreid 
dan de locoregionale lymfklieren, spreekt men van op afstand uitgezaaide ziekte en 
resteren in principe slechts palliatieve opties. Alhoewel het overgrote deel van de 
patiënten met uitgezaaide ziekte initieel met regressie of stabilisatie zal reageren op 
de diverse combinatie chemotherapieschema’s, zal er meestal binnen een jaar 
progressie optreden en bedraagt de mediane totale overleving na start van palliatieve 
behandeling gemiddeld twee tot drie jaren. 
 
Dosis intensificatie van chemotherapie heeft tot doel de hoeveelheid toegediende 
chemotherapie per tijdseenheid te verhogen om een zo optimaal mogelijk antitumor 
effect te bereiken.  
De dosis intensiteit, de dosis per kuur en de cumulatieve dosis zijn allen belangrijk, 
maar kunnen een verschillend antitumor effect hebben. Volgens Goldie en Coldman 
leidt een hoge dosisintensiteit tot een snelle en effectieve opruiming van gevoelige 
tumorcellen, waarbij een hogere dosis per kuur het risico op het ontwikkelen van 
chemotherapie resistente tumorcellen verlaagt. Norton e.a. lieten zien dat het 
groeibeloop van borstkanker overeenkomt met een Gompertze curve. In dit model 
wordt verondersteld dat patiënten met een uitgezaaide borstkanker, en dus een grote 
tumorlast, de fractie delende cellen laag is, en hierdoor de hoeveelheid gedode cellen 
per kuur beperkt is. Intervalverkorting tussen de kuren (densificatie) zou derhalve een 
mogelijkheid bieden om deze cytokinetische resistentie van de tumor te beïnvloeden.  
Chemotherapie dosisintensificatie is echter slechts beperkt mogelijk vanwege 
bijwerkingen als diepe en langdurige beenmergonderdrukking, met het risico van 
koorts en infecties. Hematopoietische groeifactoren, en speciaal Granulocyt 
Koloniestimulerende Factor (G-CSF), biedt een mogelijkheid deze bijwerking te 
overbruggen. De toevoeging van G-CSF aan de chemotherapie vermindert niet alleen 
het optreden van neutropene koorts, maar ondersteunt ook de mogelijkheid tot 
verhoging van de dosisintensiteit van cytostatica toediening.  
Dit kan langs twee wegen worden bereikt: 
1. Standaard doseringen van cytostatica, waarbij het interval tussen de kuren wordt 
verkort (densificatie). 
2. Standaard kuurinterval (veelal 3 weken), waarbij de dosering van cytostatica per 
kuur wordt verhoogd (dosis-escalatie). 
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Beide benaderingen resulteren in een hogere dosisintensiteit, maar het biologisch 
effect en de klinische relevantie kunnen verschillen. Dit werd ook beschreven door 
Henderson e.a. in zijn overzichtsartikel over het dosisintensiteit fenomeen in 
borstkanker. De relatieve voordelen van de ene versus de andere benaderingswijze 
van dosisintensificatie is niet systematisch onderzocht. 
 
Een anthracycline niet-taxaanbevattend chemotherapieschema als eerste lijn 
behandeling in gemetastaseerde borstkanker geeft een 30% tot 50% responskans, 
met een 5% tot 10% complete responskans en een mediane progressievrije overleving 
van vier tot acht maanden. Epirubicine is een anthracycline en een synthetische 
analoog van doxorubicine. Het heeft een gelijkwaardig antitumor effect maar wellicht 
een gunstiger toxiciteitprofiel in vergelijking met doxorubicine, waarbij met name 
minder cardiotoxiciteit. 
 
In Hoofdstuk 2 worden de resultaten van een vergelijkende studie van dosis escalatie 
versus densificatie, om de maximale dosisintensiteit te verkrijgen van epirubicin en 
cyclofosfamide ondersteunt met G-CSF, beschreven. De tweede doelstelling was 
inzicht te verkrijgen in de veiligheidsaspecten van deze geïntensiveerde behande-
lingen. 
In deze studie werden 49 patiënten met gemetastaseerd borstkanker behandeld met 
dagelijkse G-CSF injecties en oftewel oplopende doseringen van epirubicine en 
cyclofosfamide met gelijkblijvende kuurinterval (arm 1, dosis-escalatie), of steeds 
kortere kuurintervallen met gelijkblijvende doseringen van epirubicine en 
cyclofosfamide (arm 2, densificatie). Per kuurinterval/dosis, werd een cohort van 
minimaal 6 patiënten bestudeerd. Er werd overgegaan naar een meer geïntensiveerde 
kuurinterval/dosis indien minder dan 50% van de patiënten geconfronteerd werd met 
een dosislimiterende toxiciteit gedurende de eerste 3 kuren.  
In arm 1, bleek epirubicine/cyclofosfamide 140/800 mg/m2 in een 3 wekelijkse cyclus 
te zwaar. Vervolgens werd epirubicine/cyclofosfamide 120/700 mg/m2 onderzocht. 
Hierop kregen 2 van de 10 patiënten een dosislimiterende toxiciteit. In beide gevallen 
betrof het neutropene koorts. In arm 2 werd epirubicine/cyclofosfamide 75/500 mg/m2 
veilig toegediend in een 14 en een 12 daags kuurinterval. In het 10 daagse interval 
konden 8 van de 12 patiënten de eerste 3 kuren ondergaan zonder ernstige toxiciteit. 
In het 8 daags interval werden 7 van de 8 patiënten geconfronteerd met een 
dosislimiterende toxiciteit. Onvolledig herstel van de witte bloedcellen, en in mindere 
mate slijmvliesirritatie, waren dosislimiterend. In 21% van de patiënten behandeld in 
een korter kuurinterval werd een klinisch asymptomatische cardio-toxiciteit 
geconstateerd, hetgeen volledig herstelde bij langere opvolging.  
In combinatie met G-CSF, was epirubicine/cyclofosfamide 120/700 mg/m2 in een 3 
wekelijkse cyclus haalbaar, met een geprojecteerde dosisintensiteit van respectievelijk 
40/233 mg/m2/week. Epirubicin/cyclofosfamide 75/500 mg/m2 kon veilig iedere 10 
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dagen toegediend worden, hetgeen een hogere dosisintensiteit mogelijk maakte van 
respectievelijk 52,5/350 mg/m2/week. 
Concluderend blijkt met toevoeging van G-CSF verkorting van het kuurinterval bij 
gelijkblijvende dosering een effectievere aanpak van dosisintensificatie dan dosis-
escalatie.   
 
Naast anthracyclines, behoren de taxanen tot de meest actieve cytostatica bij de 
behandeling van gemetastaseerd borstkanker. Paclitaxel is zeer actief en vertoont 
geen kruisresistentie met andere frequent gebruikte cytostatica bij de behandeling 
van borstkanker. De combinatie van paclitaxel en doxorubicine liet in klinische fase I 
en II studies veelbelovende responspercentages zien van 83% tot 95%. De 
superioriteit van deze anthracycline-taxaan combinatie werd vervolgens bevestigd in 
vijf gerandomiseerde fase III studies, met responspercentages van 55% tot 68%, en 
een beperkte winst in de progressievrije overleving. Twee studies lieten een 
significante verbetering zien in de totale overleving, echter ten koste van een 
toename in therapie gerelateerde toxiciteit, hoofdzakelijk neutropene koorts, 
infecties en cardiotoxiciteit. 
 
Hoofdstuk 3 beschrijft het onderzoek naar de maximale dosisintensiteit van de 
epirubicin/paclitaxel combinatie middels intervalverkorting bij patiënten met 
gemetastaseerde borstkanker. Het doel van het onderzoek was de bepaling van het 
kortst haalbare chemotherapie-interval en de bepaling van het veiligheidsprofiel van 
deze benaderingswijze. 
Zesendertig patiënten met gemetastaseerde borstkanker werden in een multicenter 
fase I/II studie onderzocht. De behandeling bestond uit epirubicine 75 mg/m2 gevolgd 
door paclitaxel 135 mg/m2 (3 uur infusie) in combinatie met G-CSF (5 µgr/kg). 
Minimaal 6 patiënten werden behandeld in ieder cohort en evaluatie vond plaats over 
de eerste 3 kuren. Er werd gestart met een 14 daags chemotherapie interval en in 
opeenvolgende cohorten kon het interval verkort worden tot 10 dagen.  
Het 8 daagse interval was niet haalbaar, met name als gevolg van een incompleet 
herstel van de witte bloedcellen op de dag van de geplande volgende kuur. In het 
cohort van het 10 daagse interval kon de dosis van de paclitaxel worden verhoogd tot 
175 mg/m2. De therapie gerelateerde toxiciteit was relatief mild. Negen van 36 
patiënten ontwikkelden een dosis limiterende toxiciteit gedurende de eerste 3 kuren. 
Initieel waren dit incompleet hematologisch herstel op de dag van de geplande 
volgende kuur in vijf, neutropene koorts in één, en niet-hematologische toxiciteit in 
de resterende drie patiënten. Tijdens de eerste drie kuren waren er geen 
aanwijzingen voor cumulatieve beenmergonderdrukking. Na drie korte intervalkuren 
was er reeds sprake van een responspercentage van 53%. 
Concluderend, met de toevoeging van G-CSF lijkt intervalverkorting van chemo-
therapiekuren een haalbare aanpak van dosisintensificatie, waarbij een dosis-
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intensiteit van 52 mg/m2/week voor epirubicine en van 122 mg/m2/week voor 
paclitaxel mogelijk was. 
De effectiviteit en klinische relevantie van deze benadering zal onderzocht moeten 
worden in een fase II onderzoek.   
 
In Hoofdstuk 4 worden de twee benaderingen van dosisintensificatie, dosis-escalatie 
en densificatie, voor de combinatie van epirubicine en paclitaxel ondersteund met 
G-CSF onderzocht.  
Deze multicenter gerandomiseerde fase II studie onderzocht de volgende twee 
schema’s: epirubicine 110 mg/m2 gecombineerd met paclitaxel 200 mg/m2 in een 3 
wekelijkse cyclus (dosis-escalatie) en epirubicine 75 mg/m2 gecombineerd met 
paclitaxel 175 mg/m2 in een 10 daagse cyclus (densificatie). Patiënten met 
gemetastaseerde borstkanker en zonder eerdere palliatieve chemotherapie 
ondergingen 6 kuren chemotherapie.  
In totaal waren er 106 patiënten  evalueerbaar voor toxiciteit en 101 patiënten voor 
tumorrespons. Graad ≥ 3 bijwerkingen trad in 39% van de dosis-escalatie patiënten op 
en in 29% van de densificatie patiënten, hoofdzakelijk bestaande uit neutropene 
koorts, bloedplaatjes onderdrukking en perifere neuropathie. Asymptomatische 
hartspiertoxiciteit werd frequenter in de dosis-escalatie arm (16% vs 8%) 
gediagnosticeerd. Een mogelijke verklaring is de hogere cumulatieve dosering van 
epirubicine in de dosis-escalatie arm, naast de farmacokinetische interactie tussen 
epirubicine en paclitaxel. The mediaan toegediende cumulatieve doseringen van 
epirubicine/paclitaxel waren 656/1194 mg/m2 en 448/1045 mg/m2, de totale 
behandeltijd 126 en 61 dagen. De toegediende dosisintensiteit van 
epirubicine/paclitaxel was 36/67 mg/m2/week en 51/120 mg/m2/week, voor 
respectievelijk de dosis-escalatie arm en de densificatie arm. Beide therapieschema’s 
waren zeer effectief met een totaal tumor responspercentage van 70% of meer. Na 3 
kuren chemotherapie bedroeg deze 51% in de densificatie arm (na 1 maand 
behandeling) en 55% in the dosis-escalatie arm (na 2 maanden behandeling). Ondanks 
halvering van de behandelingsduur in de densificatie arm, en een lagere cumulatieve 
dosering van de cytostatica lijkt de progressievrije overleving (respectievelijk 6 en 7 
maanden) voor de beide behandelarmen vergelijkbaar. In de densificatie arm bedroeg 
het therapievrije interval 5 maanden, terwijl deze in de dosis-escalatie arm maar 
2 maanden was.  
Door de kortere totale behandelingstijd en minder bijwerkingen lijkt de densificatie 
benadering het voorkeurschema van dosisintensificatie te zijn.  
Wij denken dat verder onderzoek naar het concept van densificatie van 
chemotherapie in de behandeling van borstkanker aangewezen is. 
 
Adjuvante systemische therapie in bepaalde groepen patiënten met een vroeg 
stadium borstkanker, leidt tot een beperkte maar consistente verbetering in de lange 
termijn ziektevrije overleving en totale overleving. Pogingen om de dosis van de 
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cytostatica nog verder te verhogen worden ondanks ondersteuning met 
hematopoietische groeifactoren, met name belemmerd door langdurige diepe 
beenmergonderdrukking. Hoge dosis chemotherapie, gevolgd door autologe stamcel 
transplantatie biedt de mogelijkheid deze complicatie deels te omzeilen. Of deze 
behandeling leidt tot een betere ziektevrije en totale overleving was indertijd 
onduidelijk. 
 
In Hoofdstuk 5 wordt het concept van hoge dosis chemotherapie met autologe 
stamcel ondersteuning als consolidatie therapie na standaard adjuvante 
chemotherapie in borstkanker patiënten met 7 of meer aangedane axillaire 
lymfklieren onderzocht. In de periode november 1991 tot en met oktober 1995 
ondergingen 19 patiënten na chirurgische behandeling 4 standaardkuren adjuvante 
chemotherapie gevolgd door hoge dosis chemotherapie (busulfan en cyclofosfamide) 
en autologe stamcel transplantatie.  
De mediane leeftijd was 41 jaar, het mediane aantal aangedane axillaire lymfklieren 
was 11 (range 7–29) en negen patiënten hadden een oestrogeenreceptor  positieve 
tumor. Na een relatief korte mediane follow-up van 45 maanden, waren er twee 
patiënten overleden aan de complicaties van de behandeling en was er bij negen 
patiënten een terugval van de ziekte opgetreden. De mediane ziektevrije overleving 
was 16 maanden en de mediane totale overleving bedroeg 27 maanden.  
Een recente update met een mediane follow-up van meer dan 16 jaar, laat zien dat 12 
van de 19 patiënten een recidief hebben ontwikkeld en uiteindelijk aan borstkanker 
zijn overleden, resulterend in een ziektevrije overleving van 21% en totale overleving 
van 26%.  
Concluderend, is hoge dosis chemotherapie met autologe stamcel transplantatie in 
hoge risico borstkanker patiënten een toxische behandeling en laat voor de totale 
groep geen overlevingswinst zien.  
 
Hoofdstuk 6 beschrijft de resultaten van een fase II studie van HLA-matched allogene 
stamcel transplantatie na een lagere dosering chemotherapie conditionering (de 
zogenaamde reduced-intensity conditionering (RIC)) met fludarabine/cyclofosfamide 
in 15 patiënten met uitgezaaide borstkanker. Deze single center onderzoek had als 
doel de haalbaarheid, veiligheid en effectiviteit van deze behandelmethode te 
evalueren. Het pretransplantatie conditionering schema bestond uit fludarabine 
(25 mg/m2 dag -5 tot en met -1) en cyclofosfamide (60 mg/kg dag -2 en -1). Perifere 
bloed stamcellen werden verkregen van een HLA-matched broer of zus.  
Therapie gerelateerde mortaliteit trad op bij 2 patiënten (13%). De mediane 
progressievrije overleving en de totale overleving bedroegen respectievelijk 144 
dagen (43-509 dagen) en 303 dagen (122–1376 dagen). De één jaar progressievrije 
overleving was 20%, en de één jaar en twee jaar totale overleving bedroeg 
respectievelijk 40% en 20%. Een objectieve tumorrespons werd niet geobserveerd.  
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Dus, alhoewel ‘reduced-intensity conditionering’ stamcel transplantatie haalbaar is, 
lijkt de effectiviteit in deze patiënten categorie beperkt. Nieuwe klinische 
onderzoeken zijn noodzakelijk om meer inzicht te verkrijgen in de mechanismen van 
het antitumor effect in borstkanker.  
Samenvattend 
In uitgezaaide borstkanker hebben we laten zien dat de twee benaderingen van 
dosisintensificatie, densificatie en dosis escalatie, van taxaan-bevattende en niet 
taxaan-bevattende combinatie chemotherapie haalbaar is. Densificatie vergeleken 
met dosis escalatie leidt echter tot een hogere chemotherapie dosisintensiteit en een 
lagere cumulatieve dosis. Desondanks lijkt er sprake te zijn van een hogere 
effectiviteit en minder bijwerkingen bij het densificatie schema. Ook anderen hebben 
de superioriteit laten zien van een densificatie schema boven een standaard 
chemotherapie schema. Echter als gevolg van de beperkt beschikbare data, is dosis 
densificatie (nog) geen standaard behandeling . De enige uitzondering hierop vormt 
echter het cytostaticum paclitaxel. Zowel in de adjuvante als uitgezaaide setting van 
borstkanker, blijkt de wekelijkse toediening superieur aan de 3-wekelijkse toediening, 
zowel in response percentage als overleving. 
Bij borstkanker patiënten met een groot aantal positieve klieren lijkt hoge dosis 
chemotherapie met autologe beenmerg transplantatie als consolidatie na standaard 
adjuvante chemotherapie, geen overlevingswinst te bieden ten opzichte van 
conventionele adjuvante chemotherapie. Een meta-analyse van 13 gerandomiseerde 
studies liet evenmin winst zien van hoge dosis chemotherapie boven standaard 
adjuvante chemotherapie. In feite, lijkt de intensieve behandeling zelfs nadelig, met 
een toename aan sterfgevallen als gevolg van de behandeling. 
Een alternatieve benadering voor hoge dosis chemotherapie met autologe beenmerg-
transplantatie is HLA-matched allogene stamcel transplantatie na een ‘reduced 
intensity conditionering’ schema. Deze techniek blijkt haalbaar te zijn echter 
vooralsnog lijkt de effectiviteit beperkt te zijn. 
Huidige standaard behandeling 
Een recente meta-analyse van de overlevingsresultaten van 128 gerandomiseerde 
studies laat een duidelijke absolute overlevingswinst zien voor toepassing van 
anthracyclines, taxanen, nieuwe niet-taxanen cytostatica zoals capecitabine en 
gemcitabine, zowel als monotherapie en als combinatie chemotherapie. De geschatte 
winst in levensverwachting met deze nieuwe middelen varieert van 4 tot 12 maanden. 
Recente trials hebben laten zien dat in de adjuvante setting combinaties van 
anthracyclines en taxanen superieur zijn ten opzichte van de oudere chemo-
therapieschema’s. 
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Toekomstige ontwikkelingen 
In het laatste decennium hebben zich belangrijke ontwikkelingen in de 
systeembehandeling van borstkanker voorgedaan. De introductie van de derde 
generatie aromataseremmers hebben het terrein van de endocriene behandeling 
drastisch veranderd.  
Nog belangrijker was de ontdekking van de receptoren van de HER-familie, waarbij de 
HER2 receptor momenteel een zeer belangrijke doelwit is in de behandeling van 
borstkanker. Bij ongeveer 20% van de borstkanker patiënten is er sprake van een 
amplificatie van het proto-oncogeen HER2. Amplificatie/overexpressie van HER2 
voorspelt een respons op behandelingen gericht op de HER2, zoals de 
gehumaniseerde monoklonale antilichaam trastuzumab en de klein moleculaire 
tyrosine kinase remmer lapatinib.  
Andere nieuwe ontwikkelingen op het terrein van doelgerichte antitumor therapie 
betreft de Vascular Endothelial Growth Factor (VEGF) gerichte behandelingen middels 
monoklonale antilichamen of tyrosine kinase remmers en de Poly ADP Ribose 
Polymerase (PARP) remmers, met name in de triple negatieve patiënten subgroep. 
In de nabije toekomst kan het ontrafelen van de moleculaire pathways mogelijk de 
selectie van borstkankerpatiënten die voor de klassieke cytostatica zoals de 
anthracyclinen en taxanen in aanmerking komen verbeteren. Als we straks inderdaad 
in staat zijn patiënten met een chemosensitieve tumor op basis van biologische 
kenmerken te herkennen, is het wellicht mogelijk door kleine aanpassingen in het 
chemotherapieschema de uitkomst te verbeteren. Samenvattend, kan toename in 
inzichten over de moleculaire pathways mogelijk een bijdrage leveren aan toekomstig 
onderzoek naar dosis densificatie van chemotherapie in een geselecteerde patiënten 
populatie. 
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Dankwoord 
Na vele jaren van onderzoek en nog diverse jaren voor het afronden hiervan is mijn 
proefschrift eindelijk een feit.  
Velen ben ik dank verschuldigd voor hun bijdrage aan dit proefschrift.  
 
Een zeer belangrijke bijdrage hebben de patiënten geleverd die deelgenomen hebben 
aan de diverse studies, waarvoor mijn dank. 
Een aantal mensen wil ik bij naam noemen, zonder naar volledigheid te willen streven. 
Ik ga daarbij terug in de tijd.  
 
Het was Prof. dr. G.H. Blijham (toenmalig hoofd van de werkgroep Hematologie-
Oncologie) die mij begeleidde bij de eerste schreden in de medische oncologie en het 
klinische onderzoek, en mij vervolgens stimuleerde onderzoek te gaan verrichten naar 
chemotherapie dosisintensificatie. Beste Geert, ondanks het feit dat je in 1992 
Maastricht verruilde voor Utrecht en je meer ging richten op bestuurlijke activiteiten, 
bleef je nauw betrokken bij mijn onderzoek. Je kritische analyses en verrassende 
ideeën waren altijd zeer welkom. Het was voor mij een voorrecht om met jou te 
mogen samenwerken, waarvoor hartelijk dank. 
 
Prof. dr. H.C. Schouten, was na 1992 de continue factor in de begeleiding en 
ondersteuning van de diverse studies. Beste Harry, het was jouw ingenieuze idee om 
het concept van stamceltransplantatie mee te nemen in mijn onderzoeken naar 
dosisintensificatie. In al de jaren heb je steeds achter mijn onderzoeken gestaan. Jij 
hebt mij ook wegwijs gemaakt in de beginselen van de maligne hematologie. Dank 
voor de jarenlange prettige samenwerking, steun en het vertrouwen. 
 
Prof. dr. V.C.G. Tjan-Heijnen, hoofd van de onderafdeling Medische Oncologie sinds 
haar komst in september 2006, was vanaf onze “eerste kennismaking” ervan 
overtuigd dat het proefschrift binnen afzienbare tijd zou worden afgerond. Hartelijk 
dank Vivianne, het is mede dankzij jouw hulp, doelgerichtheid en vasthoudendheid 
dat mijn boekje nu klaar is. 
 
De onderzoeken waren niet mogelijk geweest zonder de actieve participatie vanuit de 
diverse deelnemende ziekenhuizen door de collega’s: dr. F.L.G. Erdkamp, dr. J.A.M.J. 
Wils, dr. C.J. Rodenburg, Prof. dr. J.W. Nortier (indertijd werkzaam in het 
Diaconessenhuis te Utrecht), Prof. dr. E.E. Voest, drs. J. Wals, drs. C.T.A.M. Knibbeler-
van Rossum (indertijd werkzaam in het St. Elisabeth ziekenhuis te Tiburg), drs. A. van 
Bochove, dr. J.Th.M. Burghouts, dr. P.H.Th.J. Slee, drs. O.J.L. Loosveld, dr. A.E.M. 
Smals, dr. R.L.H. Jansen, dr. P.S.G.J. Hupperets, dr. R. van Rijswijk, dr. G.M.J. Bos, dr. 
M. van Gelder en drs. M.A. ten Haaft. Met veel plezier en warme gevoelens denk ik 
terug aan de diverse studiebijeenkomsten ergens tussen Maastricht en Utrecht of 
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tijdens het jaarlijkse ASCO congres in de Verenigde Staten. Dank voor jullie 
betrokkenheid en inzet.   
Een speciaal woord van dank aan Prof. dr. J.W.R. Nortier, Prof. dr. E.E. Voest en Prof. 
dr. H.F.P. Hillen voor jullie bijdrage aan het mede ontwerpen van de dosisintensificatie 
studies. 
 
De sponsors van de dosisintensificatie studies waren de firma’s Amgen BV, Pharmacia 
& Upjohn en Bristol-Myers Squibb BV. Pieter Oosthoek, Jan Smeets en Gerrit 
Verhagen, hartelijk dank voor jullie nimmer aflatende ondersteuning. “Mortons” is nu 
voor mij een vast programmaonderdeel van de jaarlijkse ASCO bezoeken geworden. 
 
De datamanagers van de deelnemende ziekenhuizen en Integrale Kanker Centra’s; A. 
Epping, M. Bongers, B. Hagemans, M. Jansen, H. Leurs, C. Erdkamp, I. van Beuningen, 
M. Waber, R. Goossens, A. Huldij en A. Kroen, dank voor het zorgvuldig en tijdig 
aanleveren van de CRF’s. 
 
De leden van de beoordelingscommissie, Prof.dr.M.F. von Meyenfeldt, Prof.dr. J.B. 
Vermorken, Prof.dr. R.F.P.M. Kruitwagen en Prof. dr. P. Lambin, ben ik zeer erkentelijk 
voor de beoordeling en goedkeuring van dit proefschrift. 
 
Beste Tiny Wouters, dank voor de fraaie lay-out, de razendsnelle correcties en je 
fantastische opmerkingsgave voor foutjes in mijn proefschrift. Voor Fabiano Peltrera 
was het ontwerpen van de boekomslag een uitdaging waarin hij succesvol is geslaagd. 
 
Lieve ouders, na 6 jaar in Indonesië te hebben verbleven, namen jullie in 1966 het 
moedige en wijze besluit, dat de toekomst van onze familie in Nederland zou liggen. 
Het was een flinke stap terug, jullie moesten opnieuw beginnen. Pa was de eerste arts 
in de familie en deelde met ons zijn liefde voor dit mooie vak. Drie kinderen zijn 
vervolgens in zijn voetsporen getreden. Pa was ook degene die de mogelijkheid van 
een promotieonderzoek bij mij aankaartte, iets wat in zijn eigen loopbaan niet tot de 
mogelijkheden behoorde. Beste Pa en Ma, jullie hebben lang op deze dag moeten 
wachten, maar gelukkig kunnen jullie vandaag beiden in goede gezondheid aanwezig 
zijn. 
 
Lieve Monique, al meer dan 30 jaar mijn steun en toeverlaat. Voor mij ben je naar het 
diepe zuiden komen afzakken. Je eigen carrière, het reilen en zeilen thuis en de 
kinderen, het werd allemaal vanzelfsprekend door jou georganiseerd en 
gecombineerd. Jij was de continue factor, en droeg zorg voor een warm en gezellig 
huis voor een ieder. Daarnaast zorgde je voor de noodzakelijke afwisseling tussen 
werk en ontspanning. Dank voor je onvoorwaardelijke steun, jij was de belangrijkste 
persoon achter mijn proefschrift. 
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Tom, Roepie en Bibi, de zaterdagen zijn altijd heilig voor de familie en staat de sport 
centraal. Daarbuiten hebben jullie je vader veel achter de laptop gezien, bezig met zijn 
onderzoek of zijn werk. Nu heb ik meer tijd voor andere, wellicht belangrijkere zaken. 
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Curriculum Vitae 
Roy Iqbal Lalisang werd geboren op 1 november 1958 te Leiden. Van 1960 tot 1966 
verbleef hij in zijn vaderland, Indonesië. Hij bezocht het Bisschoppelijk College te 
Weert alwaar in 1976 het diploma Atheneum B werd behaald. Aansluitend werd de 
studie geneeskunde aan de Rijksuniversiteit te Leiden aangevangen, en werd in 1983 
het artsexamen gehaald. Hij werkte vervolgens in de periode 1983 tot 1985 als arts-
assistent niet in opleiding op de afdeling Verloskunde en Eerste Hulp van het St. Jans 
Gasthuis te Weert. Aansluitend heeft hij gedurende 2 jaar (1985-1986) gewerkt als 
arts-assistent niet in opleiding op de afdeling Heelkunde van het Westeinde 
Ziekenhuis in Den Haag. In 1987 heeft hij gedurende 6 maanden geparticipeerd aan 
een tweetal onderzoeken (echografisch appendicitis onderzoek, afdeling radiologie, 
en onderzoek naar de postoperatieve resultaten van voorste kruisbandlaesies van de 
knie, afdeling Orthopedie) in het Westeinde Ziekenhuis in Den Haag. Vervolgens 
werkte hij als arts-assistent niet in opleiding op de afdeling Cardiopulmonale Chirurgie 
van het Catharina Ziekenhuis in Eindhoven. Juni 1988 begon hij als arts-assistent niet 
in opleiding op de afdeling Interne Geneeskunde van het Academisch Ziekenhuis 
Maastricht. In april 1989 werd aldaar gestart met de opleiding tot internist (opleiders 
Prof. dr. J.A. Flendrig †, Prof. dr. A.C. Nieuwenhuijzen Kruseman, Prof. dr. H.F.P. Hillen) 
met als specifiek aandachtsgebied Medische Oncologie (opleiders dr. H.C. Schouten, 
Prof. dr. H.F.P. Hillen) en afgerond op 1 april 1995. Binnen de werkgroep Hematologie-
Oncologie, was hij aanvankelijk werkzaam als Chef de Clinique. In 1997 werd hij 
benoemd als Algemeen Consulent Medische Oncologie bij het Integraal 
Kankercentrum Limburg, met als specifieke taken de Gynaecologische Oncologie en 
de Bronchustumoren. Sedert november 1998 heeft hij diverse taken verricht naast zijn 
continue parttime aanstelling als medisch oncoloog (50% bij de werkgroep 
Hematologie-Oncologie [hoofd Prof. dr. J. Wagstaff, Prof. dr. H.C. Schouten] en sedert 
september 2006 onderafdeling Medische Oncologie [hoofd Prof. dr. V.C.G. Tjan-
Heijnen]). Hij was werkzaam als medisch hoofd van de polikliniek Interne 
Geneeskunde tot 2001 en vervolgens tot medio 2005 werkzaam als medisch 
zorgmanager van de voormalige Behandel Zorg Eenheid V (BZE V). De functie van 
Directeur-bestuurder van de Resultaat Verantwoordelijke Eenheid (RVE) Medisch 
Interventie Centrum werd ingevuld tot eind 2007. Vanaf augustus 2008 is hij 
werkzaam bij de Maastro Clinic als “linking pin” met het azM. Sedert 2002 is hij tevens 
actief betrokken bij de introductie van de producttypering van oncologische 
zorgproducten, aanvankelijk voor de Nederlandsche Internisten Vereeniging en sinds 
2009 voor de Nederlandse Vereniging voor Medische Oncologie. Binnen de 
onderafdeling Medische Oncologie heeft hij momenteel als specifieke aandachts-
gebieden de gynaecologische oncologie, de hoofd-hals oncologie, het onderwijs aan 
studenten en de DBC registratie (Diagnose Behandel Combinatie).  
Hij is gehuwd met Monique D’Agnolo. Samen hebben zij drie kinderen Tom (1991), 
Roepie (1993) en Bibi (1994). 
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